<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">PLoS</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23393428</article-id><article-id pub-id-type="pmc">3564770</article-id><article-id pub-id-type="publisher-id">PMEDICINE-D-12-02215</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.1001376</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group><subj-group><subject>Public Health</subject><subj-group><subject>Socioeconomic Aspects of Health</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Socioeconomic Inequalities in Lung Cancer Treatment: Systematic Review and Meta-Analysis</article-title><alt-title alt-title-type="running-head">Socioeconomic Inequalities in Lung Cancer Care</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Forrest</surname><given-names>Lynne F.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Adams</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wareham</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rubin</surname><given-names>Greg</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Fuse, UKCRC Centre for Translational Research in Public Health, Institute of Health &#x00026; Society, Newcastle University, Newcastle upon Tyne, United Kingdom</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Wolfson Research Institute, Durham University, Queen's Campus, Stockton on Tees, United Kingdom</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Mathers</surname><given-names>Colin D.</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>World Health Organization, Switzerland</addr-line></aff><author-notes><corresp id="cor1">* E-mail: <email>Lynne.Forrest1@ncl.ac.uk</email></corresp><fn fn-type="COI-statement"><p>GR is a member of several advisory groups for the Department of Health's National Awareness and Early Diagnosis Initiative. All other authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: LF JA MW GR. Performed the experiments: LF HW. Analyzed the data: LF. Contributed reagents/materials/analysis tools: LF. Wrote the first draft of the manuscript: LF. Contributed to the writing of the manuscript: LF JA MW GR HW. <ext-link ext-link-type="uri" xlink:href="http://www.icmje.org/">ICMJE</ext-link> criteria for authorship read and met: LF JA MW GR HW. Agree with manuscript results and conclusions: LF JA MW GR HW.</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>5</day><month>2</month><year>2013</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>e1001376</elocation-id><history><date date-type="received"><day>26</day><month>7</month><year>2012</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Forrest et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Forrest et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract abstract-type="toc"><p>In a systematic review and meta-analysis, Lynne Forrest and colleagues find that patients with lung cancer who are more socioeconomically deprived are less likely to receive surgical treatment, chemotherapy, or any type of treatment combined, compared with patients who are more socioeconomically well off, regardless of cancer stage or type of health care system.</p></abstract><abstract><sec><title>Background</title><p>Intervention-generated inequalities are unintended variations in outcome that result from the organisation and delivery of health interventions. Socioeconomic inequalities in treatment may occur for some common cancers. Although the incidence and outcome of lung cancer varies with socioeconomic position (SEP), it is not known whether socioeconomic inequalities in treatment occur and how these might affect mortality. We conducted a systematic review and meta-analysis of existing research on socioeconomic inequalities in receipt of treatment for lung cancer.</p></sec><sec><title>Methods and Findings</title><p>MEDLINE, EMBASE, and Scopus were searched up to September 2012 for cohort studies of participants with a primary diagnosis of lung cancer (ICD10 C33 or C34), where the outcome was receipt of treatment (rates or odds of receiving treatment) and where the outcome was reported by a measure of SEP. Forty-six papers met the inclusion criteria, and 23 of these papers were included in meta-analysis. Socioeconomic inequalities in receipt of lung cancer treatment were observed. Lower SEP was associated with a reduced likelihood of receiving any treatment (odds ratio [OR]&#x0200a;=&#x0200a;0.79 [95% CI 0.73 to 0.86], p&#x0003c;0.001), surgery (OR&#x0200a;=&#x0200a;0.68 [CI 0.63 to 0.75], p&#x0003c;0.001) and chemotherapy (OR&#x0200a;=&#x0200a;0.82 [95% CI 0.72 to 0.93], p&#x0200a;=&#x0200a;0.003), but not radiotherapy (OR&#x0200a;=&#x0200a;0.99 [95% CI 0.86 to 1.14], p&#x0200a;=&#x0200a;0.89), for lung cancer. The association remained when stage was taken into account for receipt of surgery, and was found in both universal and non-universal health care systems.</p></sec><sec><title>Conclusions</title><p>Patients with lung cancer living in more socioeconomically deprived circumstances are less likely to receive any type of treatment, surgery, and chemotherapy. These inequalities cannot be accounted for by socioeconomic differences in stage at presentation or by differences in health care system. Further investigation is required to determine the patient, tumour, clinician, and system factors that may contribute to socioeconomic inequalities in receipt of lung cancer treatment.</p><p>
<italic>Please see later in the article for the Editors' Summary</italic>
</p></sec></abstract><abstract abstract-type="editors-summary"><title>Editors' Summary</title><sec><title>Background</title><p>Lung cancer is the most commonly occurring cancer worldwide and the commonest cause of cancer-related death. Like all cancers, lung cancer occurs when cells begin to grow uncontrollably because of changes in their genes. The most common trigger for these changes in lung cancer is exposure to cigarette smoke. Most cases of lung cancer are non-small cell lung cancer, the treatment for which depends on the &#x0201c;stage&#x0201d; of the disease when it is detected. Stage I tumors, which are confined to the lung, can be removed surgically. Stage II tumors, which have spread to nearby lymph nodes, are usually treated with surgery plus chemotherapy or radiotherapy. For more advanced tumors, which have spread throughout the chest (stage III) or throughout the body (stage IV), surgery generally does not help to slow tumor growth and the cancer is treated with chemotherapy and radiotherapy. Small cell lung cancer, the other main type of lung cancer, is nearly always treated with chemotherapy and radiotherapy but sometimes with surgery as well. Overall, because most lung cancers are not detected until they are quite advanced, less than 10% of people diagnosed with lung cancer survive for 5 years.</p></sec><sec><title>Why Was This Study Done?</title><p>As with many other cancers, socioeconomic inequalities have been reported for both the incidence of and the survival from lung cancer in several countries. It is thought that the incidence of lung cancer is higher among people of lower socioeconomic position than among wealthier people, in part because smoking rates are higher in poorer populations. Similarly, it has been suggested that survival is worse among poorer people because they tend to present with more advanced disease, which has a worse prognosis (predicted outcome) than early disease. But do socioeconomic inequalities in treatment exist for lung cancer and, if they do, could these inequalities contribute to the poor survival rates among populations of lower socioeconomic position? In this systematic review and meta-analysis, the researchers investigate the first of these questions. A systematic review uses predefined criteria to identify all the research on a given topic; a meta-analysis is a statistical approach that combines the results of several studies.</p></sec><sec><title>What Did the Researchers Do and Find?</title><p>The researchers identified 46 published papers that studied people with lung cancer in whom receipt of treatment was reported in terms of an indicator of socioeconomic position, such as a measure of income or deprivation. Twenty-three of these papers were suitable for inclusion in a meta-analysis. Lower socioeconomic position was associated with a reduced likelihood of receiving any treatment. Specifically, the odds ratio (chance) of people in the lowest socioeconomic group receiving any treatment was 0.79 compared to people in the highest socioeconomic group. Lower socioeconomic position was also associated with a reduced chance of receiving surgery (OR&#x0200a;=&#x0200a;0.68) and chemotherapy (OR&#x0200a;=&#x0200a;0.82), but not radiotherapy. The association between socioeconomic position and surgery remained after taking cancer stage into account. That is, when receipt of surgery was examined in early-stage patients only, low socioeconomic position remained associated with reduced likelihood of surgery. Notably, the association between socioeconomic position and receipt of treatment was similar in studies undertaken in countries where health care is free at the point of service for everyone (for example, the UK) and in countries with primarily private insurance health care systems (for example, the US).</p></sec><sec><title>What Do These Findings Mean?</title><p>These findings suggest that patients in more socioeconomically deprived circumstances are less likely to receive any type of treatment, surgery, and chemotherapy (but not radiotherapy) for lung cancer than people who are less socioeconomically deprived. Importantly, these inequalities cannot be explained by socioeconomic differences in stage at presentation or by differences in health care system. The accuracy of these findings may be affected by several factors. For example, it is possible that only studies that found an association between socioeconomic position and receipt of treatment have been published (publication bias). Moreover, the studies identified did not include information regarding patient preferences, which could help explain at least some of the differences. Nevertheless, these results do suggest that socioeconomic inequalities in receipt of treatment may exacerbate socioeconomic inequalities in the incidence of lung cancer and may contribute to the observed poorer outcomes in lower socioeconomic position groups. Further research is needed to determine the system and patient factors that contribute to socioeconomic inequalities in lung cancer treatment before clear recommendations for changes to policy and practice can be made.</p></sec><sec><title>Additional Information</title><p>Please access these Web sites via the online version of this summary at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1001376">http://dx.doi.org/10.1371/journal.pmed.1001376</ext-link>.</p><list list-type="bullet"><list-item><p>The US National Cancer Institute provides information about all aspects of <ext-link ext-link-type="uri" xlink:href="http://www.cancer.gov/cancertopics/types/lung">lung cancer</ext-link> for patients and health care professionals (in English and Spanish); a monograph entitled <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/publications/ses/">Area Socioeconomic Variations in U. S. Cancer Incidence, Mortality, Stage, Treatment, and Survival, 19751999</ext-link> is available</p></list-item><list-item><p>Cancer Research UK also provides detailed information about <ext-link ext-link-type="uri" xlink:href="http://www.cancerresearchuk.org/cancer-help/type/lung-cancer/">lung cancer</ext-link> and links to other resources, such as a <ext-link ext-link-type="uri" xlink:href="http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@pol/documents/generalcontent/crukmig_1000ast-3347.pdf">policy statement on socioeconomic inequalities in cancer</ext-link> and a monograph detailing <ext-link ext-link-type="uri" xlink:href="http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@pol/documents/generalcontent/crukmig_1000ast-3344.pdf">cancer and health inequalities in the UK</ext-link>
</p></list-item><list-item><p>The UK National Health Service Choices website has a page on <ext-link ext-link-type="uri" xlink:href="http://www.nhs.uk/conditions/Cancer-of-the-lung/Pages/Introduction.aspx">lung cancer</ext-link> that includes <ext-link ext-link-type="uri" xlink:href="http://www.nhs.uk/Conditions/Cancer-of-the-lung/Pages/LungcancerrealstoriesA.aspx">personal stories</ext-link> about diagnosis and treatment</p></list-item><list-item><p>MedlinePlus provides links to other US sources of information about <ext-link ext-link-type="uri" xlink:href="http://www.nlm.nih.gov/medlineplus/lungcancer.html">lung cancer</ext-link> (in English and Spanish)</p></list-item></list></sec></abstract><funding-group><funding-statement>LF (ESRC studentship ES/I020926/1) and HW are PhD students funded by ESRC as members of Fuse, the Centre for Translational Research in Public Health (<ext-link ext-link-type="uri" xlink:href="http://www.fuse.ac.uk">www.fuse.ac.uk</ext-link>). JA, MW, and GR are funded in part as a staff member (JA), director (MW), and senior investigator (GR) of Fuse. Fuse is a UK Clinical Research Collaboration (UKCRC) Public Health Research Centre of Excellence. Funding for Fuse from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, the National Institute for Health Research, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. The views expressed in this paper do not necessarily represent those of the funders or UKCRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="25"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Lung cancer is the most commonly occurring cancer worldwide. In the USA and the UK it is the second most incident cancer <xref rid="pmed.1001376-Cancer1" ref-type="bibr">[1]</xref>,<xref rid="pmed.1001376-Howlader1" ref-type="bibr">[2]</xref>, as well as the most common cause of cancer mortality <xref rid="pmed.1001376-Howlader1" ref-type="bibr">[2]</xref>,<xref rid="pmed.1001376-Cancer2" ref-type="bibr">[3]</xref>. Survival differs internationally. In the UK, fewer than 10% of those diagnosed with lung cancer survive for 5 years <xref rid="pmed.1001376-Cancer2" ref-type="bibr">[3]</xref>,<xref rid="pmed.1001376-Coleman1" ref-type="bibr">[4]</xref>, with higher survival rates found in Nordic countries <xref rid="pmed.1001376-Coleman1" ref-type="bibr">[4]</xref>,<xref rid="pmed.1001376-Verdecchia1" ref-type="bibr">[5]</xref>, the USA <xref rid="pmed.1001376-Howlader1" ref-type="bibr">[2]</xref>,<xref rid="pmed.1001376-Verdecchia1" ref-type="bibr">[5]</xref>, Australia, and Canada <xref rid="pmed.1001376-Coleman1" ref-type="bibr">[4]</xref>.</p><p>Lung cancers are classified into small cell (SCLC) and non-small cell (NSCLC) lung cancers. NSCLC is more common than SCLC and has a better survival rate <xref rid="pmed.1001376-NICE1" ref-type="bibr">[6]</xref>. National Institute for Health and Clinical Excellence (NICE) guidelines recommend radical surgery for stage I or II NSCLC <xref rid="pmed.1001376-NICE1" ref-type="bibr">[6]</xref>. Chemotherapy and radiotherapy are recommended for later-stage NSCLC patients and are the treatments of choice for SCLC <xref rid="pmed.1001376-NICE1" ref-type="bibr">[6]</xref>. Treatment intervention with surgery, chemotherapy, or radiotherapy has been shown to improve lung cancer survival <xref rid="pmed.1001376-NICE1" ref-type="bibr">[6]</xref>.</p><p>Socioeconomic inequalities in incidence of, and survival from, the majority of cancers have been reported <xref rid="pmed.1001376-Cancer1" ref-type="bibr">[1]</xref>,<xref rid="pmed.1001376-Cancer2" ref-type="bibr">[3]</xref>,<xref rid="pmed.1001376-Rachet1" ref-type="bibr">[7]</xref>. A recent non-systematic review revealed socioeconomic inequalities in receipt of treatment for colorectal cancer <xref rid="pmed.1001376-Aarts1" ref-type="bibr">[8]</xref>, and it has been suggested that socioeconomic differences in access to treatment might at least partially explain socioeconomic differences in survival <xref rid="pmed.1001376-Woods1" ref-type="bibr">[9]</xref>. Unintended variations in outcome that result from the way that health interventions are organised and delivered have been described as intervention-generated inequalities <xref rid="pmed.1001376-White1" ref-type="bibr">[10]</xref>.</p><p>Incidence of lung cancer is higher <xref rid="pmed.1001376-Cancer1" ref-type="bibr">[1]</xref>,<xref rid="pmed.1001376-Sidorchuk1" ref-type="bibr">[11]</xref>, and survival poorer <xref rid="pmed.1001376-Rachet1" ref-type="bibr">[7]</xref>, in the most deprived patient groups. However, it is not known whether socioeconomic inequalities in receipt of treatment exist for lung cancer and, if so, what contribution they make to overall socioeconomic inequalities in outcome. In order to explore the first of these questions, we undertook a systematic review and meta-analysis of cohort studies examining the association between socioeconomic position (SEP) and receipt of lung cancer treatment.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>A protocol (see <xref ref-type="supplementary-material" rid="pmed.1001376.s012">Text S2</xref>) was developed and systematic methods were used to identify relevant studies, assess study eligibility for inclusion, and evaluate study quality. The review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines <xref rid="pmed.1001376-Moher1" ref-type="bibr">[12]</xref> (see <xref ref-type="supplementary-material" rid="pmed.1001376.s011">Text S1</xref> for PRISMA checklist).</p><sec id="s2a"><title>Literature Search</title><p>The online databases of MEDLINE and EMBASE were searched up to September 2012 (see <xref ref-type="supplementary-material" rid="pmed.1001376.s010">Table S1</xref> for full search strategies). No language restriction was applied. A search of Scopus uncovered no further papers. Additional studies were identified by reviewing the reference lists of all included studies and by using a forward citation search to identify more recent studies that had cited included studies. EndNote X5 software was used to manage the references.</p></sec><sec id="s2b"><title>Study Eligibility</title><p>Studies that met the following criteria were included in the review: primary, cohort studies of participants with a primary diagnosis of lung cancer (ICD10 C33 or C34) reported separately from other cancers; published in a peer-reviewed journal; where at least one reported outcome was receipt of treatment (measured by rates or odds of receiving treatment); and where receipt of this outcome was reported by a measure of SEP. Any curative or palliative treatment for lung cancer including surgery, chemotherapy, and radiotherapy was included.</p><p>Studies where SEP was included as a descriptive variable or confounder, but where outcomes for receipt of treatment by SEP were not presented, were not eligible for inclusion, but the authors were contacted to determine whether relevant data were available that might allow for inclusion in the review.</p><p>Studies where multivariable analysis was conducted (and included control for a minimum of age and sex as confounders); receipt of treatment was compared to not receiving treatment; odds ratios (ORs) and 95% confidence intervals (CIs) of receipt of treatment in low compared to high SEP were calculated; and SEP was not further stratified by another variable, were considered suitable for inclusion in meta-analysis.</p><p>Acceptable measures of SEP were: area-based indices of deprivation (e.g., Index of Multiple Deprivation [IMD], Townsend Score, Carstairs Index); and area or individual measures of income, poverty, or education level.</p><p>Multiple papers using the same or overlapping study data were included. Sensitivity analyses were conducted including all eligible papers and using different combinations of included papers, but only data from the better quality or more detailed paper in each overlapping study group were included in the final meta-analyses. Sensitivity meta-analyses are included in the supplemental material.</p></sec><sec id="s2c"><title>Study Selection and Data Extraction</title><p>Studies obtained from the database searches were independently assessed by two researchers (LFF and HW) in three phases: title, abstract, and full paper screening. Any disagreements at any of the screening stages were resolved by discussion between the two researchers in the first instance and with a third reviewer (JA) if agreement could not be reached. Data extraction was carried out by LFF using an Access database pro-forma developed for this purpose, and double-checked by HW.</p><p>There is evidence to suggest that health insurance status is an important factor relating to access to lung cancer care in countries such as the USA that rely on insurance-based health care systems <xref rid="pmed.1001376-Slatore1" ref-type="bibr">[13]</xref>. Insurance status is less relevant and rarely measured in most other countries. Therefore, three analytical categories were developed a priori: studies conducted in a universal health care system (UHCS), free at the point of access (similar to the UK); studies conducted in countries with primarily private insurance health care systems (non-UHCS, similar to the USA) <xref rid="pmed.1001376-Donaldson1" ref-type="bibr">[14]</xref>; and studies conducted in countries with social insurance health care systems (similar to many European countries). No studies were identified that fell into the third category.</p></sec><sec id="s2d"><title>Study Quality</title><p>A study quality tool, adapted from existing quality tools <xref rid="pmed.1001376-SIGN1" ref-type="bibr">[15]</xref>,<xref rid="pmed.1001376-Vandenbroucke1" ref-type="bibr">[16]</xref>, was used to divide studies into six quality categories, with 1 being the lowest, and 6 the highest, quality (see <xref ref-type="supplementary-material" rid="pmed.1001376.s013">Text S3</xref>). Quality assessment was carried out by LFF and checked by HW.</p><p>Cohort studies reporting only univariable analysis are of lower quality in terms of their ability to control for confounding. Only studies conducting multivariable analysis (quality scores 3&#x02013;6) were included in the meta-analysis. All studies that met the inclusion criteria were analysed in the narrative synthesis.</p></sec><sec id="s2e"><title>Statistical Analysis</title><p>Trends in receipt of treatment across SEP groups were described in the narrative analysis of all studies that met the inclusion criteria.</p><p>Meta-analysis of eligible studies was undertaken using Cochrane Collaboration Review Manager 5.1. Natural logs of the ORs and their standard errors (SEs) were calculated for use in forest plots. Random-effects meta-analysis of the odds of treatment in the lowest compared to the highest SEP group was conducted. Where a study reported the most deprived class as the comparator, reverse ORs were calculated. Studies that presented a single OR as either an OR for a one unit increase in deprivation score or incremental quintile increase in income were not included.</p><p>Subgroup analyses by treatment type and health care system were conducted. In meta-analyses where a &#x0201c;substantial&#x0201d; percentage <xref rid="pmed.1001376-The1" ref-type="bibr">[17]</xref> of the variability appeared to be due to the heterogeneity of the studies rather than to chance, further subgroup analyses by stage, histology, and quality score were conducted, where appropriate, in order to examine potential sources of heterogeneity. A funnel plot was used to assess potential publication bias.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Included Papers/Studies</title><p>A total of 46 papers met the inclusion criteria and were included in the review (see the PRISMA flow diagram [<xref ref-type="fig" rid="pmed-1001376-g001">Figure 1</xref>]). Twenty-eight papers were from UHCS countries (<xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref> and <xref ref-type="table" rid="pmed-1001376-t002">2</xref>). Of these, 19 UK papers examined 13 study populations, although as these included national and regional populations from different sources, there was some further population overlap. One UK paper also compared treatment in Scotland and Canada <xref rid="pmed.1001376-Erridge1" ref-type="bibr">[18]</xref>. A further nine papers from Canada (2), Sweden (1), Australia (1), Italy (1), France (1), and New Zealand (3) were included. The three New Zealand papers all examined the same population.</p><fig id="pmed-1001376-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.g001</object-id><label>Figure 1</label><caption><title>Flow diagram of study selection and exclusion.</title><p>CI, confidence interval; SEP, socioeconomic position.</p></caption><graphic xlink:href="pmed.1001376.g001"/></fig><table-wrap id="pmed-1001376-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t001</object-id><label>Table 1</label><caption><title>Characteristics of included studies potentially suitable for meta-analysis (universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t001-1" xlink:href="pmed.1001376.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Paper</td><td align="left" rowspan="1" colspan="1">Country of Study</td><td align="left" rowspan="1" colspan="1">Data Source (s)</td><td align="left" rowspan="1" colspan="1">Population Included</td><td align="left" rowspan="1" colspan="1">Years of Diagnosis</td><td align="left" rowspan="1" colspan="1">Measure of SEP</td><td align="left" rowspan="1" colspan="1">No. of SEP groups</td><td align="left" rowspan="1" colspan="1">Treatment given within</td><td align="left" rowspan="1" colspan="1">Age Range</td><td colspan="5" align="left" rowspan="1">Confounders Controlled For:</td><td align="left" rowspan="1" colspan="1">Quality Score</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Stage</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2010 <xref rid="pmed.1001376-Berglund1" ref-type="bibr">[19]</xref>
</td><td align="left" rowspan="1" colspan="1">Sweden</td><td align="left" rowspan="1" colspan="1">Regional Lung Cancer Register (RLCR) - Sweden, Cause of Death Register and LISA (insurance and demographics)</td><td align="left" rowspan="1" colspan="1">Uppsala/Orebro region in central Sweden</td><td align="left" rowspan="1" colspan="1">1996&#x02013;2004</td><td align="left" rowspan="1" colspan="1">Education level<xref ref-type="table-fn" rid="nt102">a</xref>
</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">30+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Performance status, year of diagnosis, smoking status</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2012 <xref rid="pmed.1001376-Berglund2" ref-type="bibr">[22]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">Thames Cancer Registry, HES, LUCADA</td><td align="left" rowspan="1" colspan="1">South-east England</td><td align="left" rowspan="1" colspan="1">2006&#x02013;2008</td><td align="left" rowspan="1" colspan="1">IMD 2007 income domain</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">0&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Campbell et al, 2002 <xref rid="pmed.1001376-Campbell1" ref-type="bibr">[35]</xref>
</td><td align="left" rowspan="1" colspan="1">Scotland</td><td align="left" rowspan="1" colspan="1">Scottish Cancer Registry and hospital case notes</td><td align="left" rowspan="1" colspan="1">Random sample from North/NE Scotland (with hospital record)</td><td align="left" rowspan="1" colspan="1">1995&#x02013;1996</td><td align="left" rowspan="1" colspan="1">Carstairs Index</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">12 months</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Health board, distance to cancer centre, mode of admission</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Crawford et al, 2009 <xref rid="pmed.1001376-Crawford1" ref-type="bibr">[36]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">Northern and Yorkshire Cancer Registry and Information Service (NYCRIS)</td><td align="left" rowspan="1" colspan="1">Northern and Yorkshire region</td><td align="left" rowspan="1" colspan="1">1994&#x02013;2002</td><td align="left" rowspan="1" colspan="1">IMD 2004 (access to services domain removed)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Travel time (but overall results not stratified by travel time used here). Histology not included in receipt of any treatment analysis.</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Erridge et al, 2002 <xref rid="pmed.1001376-Erridge2" ref-type="bibr">[37]</xref>
</td><td align="left" rowspan="1" colspan="1">Scotland</td><td align="left" rowspan="1" colspan="1">Scottish Cancer Registry and medical records</td><td align="left" rowspan="1" colspan="1">Scotland (with hospital record)</td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">Carstairs Index</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">&#x0003c;60&#x02013; 80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Health board (not inc in receipt of radiotherapy), diagnosis by specialist, management by oncologist</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Erridge et al, 2009 <xref rid="pmed.1001376-Erridge1" ref-type="bibr">[18]</xref>
</td><td align="left" rowspan="1" colspan="1">Scotland/Canada</td><td align="left" rowspan="1" colspan="1">Scottish Cancer Registry and medical records; British Columbia Cancer Registry</td><td align="left" rowspan="1" colspan="1">Scotland/British Columbia</td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">Carstairs Index/average household income</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">&#x0003c;60&#x02013; 80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Travel time, CT scan</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Gregor et al, 2001 <xref rid="pmed.1001376-Gregor1" ref-type="bibr">[38]</xref>
</td><td align="left" rowspan="1" colspan="1">Scotland</td><td align="left" rowspan="1" colspan="1">Scottish Cancer Registry and medical records</td><td align="left" rowspan="1" colspan="1">Scotland (with hospital record)</td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">Carstairs Index</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">&#x0003c;60&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Referral to specialist within 6 months of diagnosis</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2003 <xref rid="pmed.1001376-Jack1" ref-type="bibr">[39]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">Thames Cancer Registry</td><td align="left" rowspan="1" colspan="1">South-east England</td><td align="left" rowspan="1" colspan="1">1995&#x02013;1999</td><td align="left" rowspan="1" colspan="1">Townsend (median score per health authority)</td><td align="left" rowspan="1" colspan="1">Contin-uous<xref ref-type="table-fn" rid="nt103">b</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;35&#x02013;85+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">First hospital visited is a radiotherapy centre, basis of diagnosis, incidence. Health authority/hospital used as 2<sup>nd</sup> level in multi-level model.</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2006 <xref rid="pmed.1001376-Jack2" ref-type="bibr">[40]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">Thames Cancer Registry and medical records</td><td align="left" rowspan="1" colspan="1">South-east London (with hospital record)</td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">IMD 2000</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">&#x0003c;55&#x02013;85+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Consultant specialty, basis of diagnosis (hospital, number of symptoms in some analyses)</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Jones et al,2008 <xref rid="pmed.1001376-Jones1" ref-type="bibr">[41]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">Northern and Yorkshire Cancer Registry and Information Service (NYCRIS)</td><td align="left" rowspan="1" colspan="1">Northern and Yorkshire region</td><td align="left" rowspan="1" colspan="1">1994&#x02013;2002</td><td align="left" rowspan="1" colspan="1">IMD 2004 (access to services domain removed)</td><td align="left" rowspan="1" colspan="1">Contin-uous<xref ref-type="table-fn" rid="nt104">c</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Travel time to hospital</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Mahmud et al, 2003 <xref rid="pmed.1001376-Mahmud1" ref-type="bibr">[42]</xref>
</td><td align="left" rowspan="1" colspan="1">Ireland</td><td align="left" rowspan="1" colspan="1">National Cancer Registry of Ireland (NCRI)</td><td align="left" rowspan="1" colspan="1">Republic of Ireland</td><td align="left" rowspan="1" colspan="1">1994&#x02013;1998</td><td align="left" rowspan="1" colspan="1">SAHRU area-based material deprivation index</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">15&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Health board, year of diagnosis</td><td align="left" rowspan="1" colspan="1">4/2<xref ref-type="table-fn" rid="nt105">d</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">McMahon et al, 2011 <xref rid="pmed.1001376-McMahon1" ref-type="bibr">[43]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">Eastern Cancer Registry and Information Centre (ECRIC)</td><td align="left" rowspan="1" colspan="1">East of England</td><td align="left" rowspan="1" colspan="1">1995&#x02013;2006</td><td align="left" rowspan="1" colspan="1">IMD 2004 (access to services domain removed)</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;60&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Year of diagnosis</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Pollock &#x00026;Vickers, 1998 <xref rid="pmed.1001376-Pollock1" ref-type="bibr">[44]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">HES FCEs</td><td align="left" rowspan="1" colspan="1">North/South Thames (admitted to hospital)</td><td align="left" rowspan="1" colspan="1">1992&#x02013;1995</td><td align="left" rowspan="1" colspan="1">Townsend</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;100</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Hospital, mode of admission</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Raine et al, 2010 <xref rid="pmed.1001376-Raine1" ref-type="bibr">[45]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">HES FCEs</td><td align="left" rowspan="1" colspan="1">England (admitted to hospital)</td><td align="left" rowspan="1" colspan="1">1999&#x02013;2006</td><td align="left" rowspan="1" colspan="1">IMD</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">50&#x02013; 90+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Trust, year of admission, mode of admission</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Riaz et al, 2012 <xref rid="pmed.1001376-Riaz1" ref-type="bibr">[34]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">NCIN/UKACR cancer registries</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">2004&#x02013;2006</td><td align="left" rowspan="1" colspan="1">IMD 2004</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">0&#x02013; 85+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Government Office Region</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Rich et al, 2011(1) <xref rid="pmed.1001376-Rich2" ref-type="bibr">[46]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">LUCADA supplied by 157 NHS trusts</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">2004&#x02013;2007</td><td align="left" rowspan="1" colspan="1">Townsend</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Performance status. Adjusted for clustering by NHS trust</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Rich et al, 2011(2) <xref rid="pmed.1001376-Rich1" ref-type="bibr">[21]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">LUCADA and HES</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">2004&#x02013;2008</td><td align="left" rowspan="1" colspan="1">Townsend</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">30&#x02013;100</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, surgery centre, radiotherapy centre, trial entry. Adjusted for clustering by NHS trust</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Stevens et al, 2007 <xref rid="pmed.1001376-Stevens1" ref-type="bibr">[23]</xref>
</td><td align="left" rowspan="1" colspan="1">New Zealand</td><td align="left" rowspan="1" colspan="1">Regional hospital and oncology databases checked against NZ cancer registry</td><td align="left" rowspan="1" colspan="1">Auckland-Northland region patients managed in secondary care</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">NZ Deprivation Index</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;60&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, private sector care, care discussed at MDM</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Stevens et al, 2008 <xref rid="pmed.1001376-Stevens2" ref-type="bibr">[47]</xref>
</td><td align="left" rowspan="1" colspan="1">New Zealand</td><td align="left" rowspan="1" colspan="1">Regional hospital and oncology databases checked against NZ cancer registry</td><td align="left" rowspan="1" colspan="1">Auckland-Northland region patients managed in secondary care</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">NZ Deprivation Index</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;60&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, private sector care, ethnicity</td><td align="left" rowspan="1" colspan="1">5</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Quality score ranges from 1 (lowest quality) to 6 (highest quality).</p></fn><fn id="nt102"><label>a</label><p>Socioeconomic index (SEI) and household income also measured but individual education level used in analyses as it contained least missing data.</p></fn><fn id="nt103"><label>b</label><p>Odds ratio for 1 unit increase in deprivation score, range unknown.</p></fn><fn id="nt104"><label>c</label><p>Odds ratio for 1 unit increase in deprivation score, range 1&#x02013;80.</p></fn><fn id="nt105"><label>d</label><p>Quality score 4 where adjusted OR used and 2 where unadjusted rates used.</p></fn><fn id="nt106"><label/><p>HES, Hospital Episode Statistics; HES FCE, Hospital Episode Statistics Finished Consultant Episode; IMD, Index of Multiple Deprivation; LUCADA, Lung Cancer Audit; MDM, multi-disciplinary meeting; NCIN/UKACR, National Cancer Information Network/UK Association of Cancer Registries; NR, not reported; OR, odds ratio; SEP, socioeconomic position; UHCS, universal health care system.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pmed-1001376-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t002</object-id><label>Table 2</label><caption><title>Characteristics of included studies not suitable for meta-analysis (universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t002-2" xlink:href="pmed.1001376.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Paper</td><td align="left" rowspan="1" colspan="1">Country of Study</td><td align="left" rowspan="1" colspan="1">Data Source (s)</td><td align="left" rowspan="1" colspan="1">Population Included</td><td align="left" rowspan="1" colspan="1">Years of Diagnosis</td><td align="left" rowspan="1" colspan="1">Measure of SEP</td><td align="left" rowspan="1" colspan="1">No of SEP Groups</td><td align="left" rowspan="1" colspan="1">Treatment Given Within</td><td align="left" rowspan="1" colspan="1">Age Range</td><td colspan="5" align="left" rowspan="1">Confounders Controlled For:</td><td align="left" rowspan="1" colspan="1">Reason for Exclusion</td><td align="left" rowspan="1" colspan="1">Quality score</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Stage</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Battersby et al, 2004 <xref rid="pmed.1001376-Battersby1" ref-type="bibr">[48]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">HES and East Anglian Cancer Intelligence Unit</td><td align="left" rowspan="1" colspan="1">17 PCTs in Norfolk, Suffolk and Cambridgeshire with HES record</td><td align="left" rowspan="1" colspan="1">1997&#x02013;2000</td><td align="left" rowspan="1" colspan="1">IMD (weighted average for PCT)</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Incidence</td><td align="left" rowspan="1" colspan="1">Rate correlated against deprivation, by sex</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Bendzsak et al, 2011 <xref rid="pmed.1001376-Bendzsak1" ref-type="bibr">[49]</xref>
</td><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">Ontario Cancer Registry linked to CIHI hospital data, Insurance data and RPD database</td><td align="left" rowspan="1" colspan="1">Ontario</td><td align="left" rowspan="1" colspan="1">2003&#x02013;2004</td><td align="left" rowspan="1" colspan="1">Neighbourhood income</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">12 months</td><td align="left" rowspan="1" colspan="1">20&#x02013;75+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td><td align="left" rowspan="1" colspan="1">Univariable rate</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Cartman et al, 2002 <xref rid="pmed.1001376-Cartman1" ref-type="bibr">[50]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">Northern and Yorkshire Cancer Registry and Information Service (NYCRIS)</td><td align="left" rowspan="1" colspan="1">Yorkshire region</td><td align="left" rowspan="1" colspan="1">1986&#x02013;1994</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;65&#x02013;75+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td><td align="left" rowspan="1" colspan="1">Univariable rate</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Hui et al, 2005 <xref rid="pmed.1001376-Hui1" ref-type="bibr">[51]</xref>
</td><td align="left" rowspan="1" colspan="1">Australia</td><td align="left" rowspan="1" colspan="1">NSW Central Cancer Registry and hospital records</td><td align="left" rowspan="1" colspan="1">Residents of two area Health Services</td><td align="left" rowspan="1" colspan="1">1996</td><td align="left" rowspan="1" colspan="1">SEIFA-IRSD</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;50&#x02013;70+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td><td align="left" rowspan="1" colspan="1">Univariable rate</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Madelaine et al, 2002 <xref rid="pmed.1001376-Madelaine1" ref-type="bibr">[52]</xref>
</td><td align="left" rowspan="1" colspan="1">France</td><td align="left" rowspan="1" colspan="1">Manche Dept Cancer Registry</td><td align="left" rowspan="1" colspan="1">Manche</td><td align="left" rowspan="1" colspan="1">1997&#x02013;1999</td><td align="left" rowspan="1" colspan="1">INSEE</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;54&#x02013;75+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Urban/rural</td><td align="left" rowspan="1" colspan="1">Unemployed used as low SEP group and SEP group 2 used as baseline</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Pagano et al, 2010 <xref rid="pmed.1001376-Pagano1" ref-type="bibr">[53]</xref>
</td><td align="left" rowspan="1" colspan="1">Italy</td><td align="left" rowspan="1" colspan="1">Piedmont Cancer Registry of Turin</td><td align="left" rowspan="1" colspan="1">Turin</td><td align="left" rowspan="1" colspan="1">2000&#x02013;2003</td><td align="left" rowspan="1" colspan="1">Education level</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">12 months</td><td align="left" rowspan="1" colspan="1">&#x0003c;65&#x02013;75+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Marital status</td><td align="left" rowspan="1" colspan="1">Different comparator &#x02013; <italic>other</italic> not <italic>no</italic> treatment</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Patel et al, 2007 <xref rid="pmed.1001376-Patel1" ref-type="bibr">[54]</xref>
</td><td align="left" rowspan="1" colspan="1">England</td><td align="left" rowspan="1" colspan="1">Thames Cancer Registry</td><td align="left" rowspan="1" colspan="1">Southeast England</td><td align="left" rowspan="1" colspan="1">1994&#x02013;2003</td><td align="left" rowspan="1" colspan="1">IMD</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">0&#x02013;100</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Cancer network, year of diagnosis</td><td align="left" rowspan="1" colspan="1">Adjusted rates with no CIs. Possible errors in numbers.</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Stevens et al, 2009 <xref rid="pmed.1001376-Stevens3" ref-type="bibr">[55]</xref>
</td><td align="left" rowspan="1" colspan="1">New Zealand</td><td align="left" rowspan="1" colspan="1">Regional hospital and oncology databases checked against NZ cancer Registry listing</td><td align="left" rowspan="1" colspan="1">Auckland-Northland region patients managed in secondary care</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">NZ Deprivation Index</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;60&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td><td align="left" rowspan="1" colspan="1">Univariable OR. Multivariable SEP results not shown</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Younis et al, 2008 <xref rid="pmed.1001376-Younis1" ref-type="bibr">[56]</xref>
</td><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">Nova Scotia cancer registry and chart review</td><td align="left" rowspan="1" colspan="1">Nova Scotia</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">Median household income</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">65&#x02013;75+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, performance status, hospital, surgery type, post-op complications, surgeon, medical oncology, education level, distance to cancer centre, marital status, smoking history</td><td align="left" rowspan="1" colspan="1">Univariable rate. Multivariable OR only for referral by SEP</td><td align="left" rowspan="1" colspan="1">2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt107"><label/><p>Quality scores range from 1 (lowest quality) to 6 (highest quality).</p></fn><fn id="nt108"><label/><p>CI, confidence interval; HES, Hospital Episode Statistics; IMD, Index of Multiple Deprivation; NR, not reported; NSW, New South Wales; OR, odds ratio; PCT, Primary Care Trust; SEIA-IRSD, Socioeconomic Indexes for Areas - Index of Relative Social Disadvantage; SEP, socioeconomic position; UHCS, universal health care system.</p></fn></table-wrap-foot></table-wrap><p>Eighteen papers were from non-UHCSs, all of which were from the USA (<xref ref-type="table" rid="pmed-1001376-t003">Tables 3</xref> and <xref ref-type="table" rid="pmed-1001376-t004">4</xref>). The majority of non-UHCS papers used sub-groups of the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database population and, again, some population overlap was found.</p><table-wrap id="pmed-1001376-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t003</object-id><label>Table 3</label><caption><title>Characteristics of included studies potentially suitable for meta-analysis (non-universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t003-3" xlink:href="pmed.1001376.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Paper</td><td align="left" rowspan="1" colspan="1">Country of Study</td><td align="left" rowspan="1" colspan="1">Data Source (s)</td><td align="left" rowspan="1" colspan="1">Population Included</td><td align="left" rowspan="1" colspan="1">Years of Diagnosis</td><td align="left" rowspan="1" colspan="1">Measure of SEP</td><td align="left" rowspan="1" colspan="1">No of SEP Groups</td><td align="left" rowspan="1" colspan="1">Treatment Given Within</td><td align="left" rowspan="1" colspan="1">Age Range</td><td colspan="5" align="left" rowspan="1">Confounders Controlled For:</td><td align="left" rowspan="1" colspan="1">Quality Score</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Stage</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bradley et al, 2008 <xref rid="pmed.1001376-Bradley1" ref-type="bibr">[57]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Michigan Cancer Registry and Michigan Medicare and Medicaid data</td><td align="left" rowspan="1" colspan="1">Medicare and Medicare/Medicaid patients in Michigan</td><td align="left" rowspan="1" colspan="1">1997&#x02013;2000</td><td align="left" rowspan="1" colspan="1">Census tract median household income (high v low)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">66&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, insurance type, ethnicity, urban/rural</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Davidoff et al, 2010 <xref rid="pmed.1001376-Davidoff1" ref-type="bibr">[58]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients from 16 SEER registries</td><td align="left" rowspan="1" colspan="1">1997&#x02013;2002</td><td align="left" rowspan="1" colspan="1">Census tract median household income</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">90 days</td><td align="left" rowspan="1" colspan="1">66&#x02013;85+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, performance status, ethnicity, marital status, rural/urban, prior Medicaid, tumour grade</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Earle et al, 2000 <xref rid="pmed.1001376-Earle1" ref-type="bibr">[59]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients from 11 SEER registries</td><td align="left" rowspan="1" colspan="1">1991&#x02013;1993</td><td align="left" rowspan="1" colspan="1">Census tract median household income(increase in OR per quintile)</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4 months</td><td align="left" rowspan="1" colspan="1">65&#x02013;104</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, year of diagnosis, ethnicity, rural/urban, teaching hospital, SEER area</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Esnoala et al, 2008 <xref rid="pmed.1001376-Esnaola1" ref-type="bibr">[60]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">South Carolina central cancer Registry linked to inpatient and outpatient surgery files</td><td align="left" rowspan="1" colspan="1">South Carolina</td><td align="left" rowspan="1" colspan="1">1996&#x02013;2002</td><td align="left" rowspan="1" colspan="1">Income, zip code level (poverty/not living in poverty)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;50&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, year of diagnosis, insurance type, ethnicity, rural/urban, education, marital status, tumour location</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Greenwald et al, 1998 <xref rid="pmed.1001376-Greenwald1" ref-type="bibr">[61]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry</td><td align="left" rowspan="1" colspan="1">3 (Detroit, San Francisco, Seattle) out of 9 SEER registries</td><td align="left" rowspan="1" colspan="1">1978&#x02013;1982</td><td align="left" rowspan="1" colspan="1">Census tract median household income (increase in OR per decile)</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;&#x0200a;=&#x0200a;75</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Performance status, ethnicity</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Hardy et al, 2009 <xref rid="pmed.1001376-Hardy1" ref-type="bibr">[62]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients from 17 SEER registries</td><td align="left" rowspan="1" colspan="1">1991&#x02013;2002</td><td align="left" rowspan="1" colspan="1">% individuals below poverty line at census tract level</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">65&#x02013;85+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, year of diagnosis, ethnicity, marital status, SEER area, other treatment</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Hayman et al, 2007 <xref rid="pmed.1001376-Hayman1" ref-type="bibr">[63]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients from 11 SEER registries</td><td align="left" rowspan="1" colspan="1">1991&#x02013;1996</td><td align="left" rowspan="1" colspan="1">Census tract median household income</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4 months/2 years</td><td align="left" rowspan="1" colspan="1">65&#x02013;85+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, year of diagnosis, ethnicity, SEER area, hospitalisation, teaching hospital, distance to nearest RT centre, receipt of chemotherapy</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Lathan et al, 2008 <xref rid="pmed.1001376-Lathan1" ref-type="bibr">[64]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients from 11 SEER registries</td><td align="left" rowspan="1" colspan="1">1991&#x02013;1999</td><td align="left" rowspan="1" colspan="1">Census tract median household income (inc in OR per quintile)</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">65+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, SEER registry, urban, non-profit hospital, patient volume, % of black patients in hospital</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Polednak, 2001 <xref rid="pmed.1001376-Polednak1" ref-type="bibr">[65]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Connecticut Tumor Registry (SEER) and inpatient hospital discharge database (HDD)</td><td align="left" rowspan="1" colspan="1">Connecticut</td><td align="left" rowspan="1" colspan="1">1992&#x02013;1997</td><td align="left" rowspan="1" colspan="1">Census tract poverty rate</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;55&#x02013;80+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, marital status</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Smith et al, 1995 <xref rid="pmed.1001376-Smith1" ref-type="bibr">[66]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Virginia Cancer Registry and Medicare claims database</td><td align="left" rowspan="1" colspan="1">Medicare patients from Virginia cancer registry</td><td align="left" rowspan="1" colspan="1">1985&#x02013;1989</td><td align="left" rowspan="1" colspan="1">Census tract: median household income by race and age</td><td align="left" rowspan="1" colspan="1">Contin-uous<xref ref-type="table-fn" rid="nt110">a</xref>
</td><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1">65&#x02013;85+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, county of residence, distance to oncologist</td><td align="left" rowspan="1" colspan="1">5</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt109"><label/><p>Quality scores range from 1 (lowest quality) to 6 (highest quality).</p></fn><fn id="nt110"><label>a</label><p>Odds ratio for increase per $10,000 income.</p></fn><fn id="nt111"><label/><p>CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; SEER, National Cancer Institute's Surveillance, Epidemiology and End Results database; SEP, socioeconomic position.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pmed-1001376-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t004</object-id><label>Table 4</label><caption><title>Characteristics of included studies not suitable for meta-analysis (non-universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t004-4" xlink:href="pmed.1001376.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Paper</td><td align="left" rowspan="1" colspan="1">Country</td><td align="left" rowspan="1" colspan="1">Data Source (s)</td><td align="left" rowspan="1" colspan="1">Population Included</td><td align="left" rowspan="1" colspan="1">Years of Diagnosis</td><td align="left" rowspan="1" colspan="1">Measure of SEP</td><td align="left" rowspan="1" colspan="1">No of SEP Groups</td><td align="left" rowspan="1" colspan="1">Treatment Given Within</td><td align="left" rowspan="1" colspan="1">Age Range</td><td colspan="5" align="left" rowspan="1">Confounders Controlled For:</td><td align="left" rowspan="1" colspan="1">Reasons for Exclusion</td><td align="left" rowspan="1" colspan="1">Quality Score</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Stage</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bach et al, 1999 <xref rid="pmed.1001376-Bach1" ref-type="bibr">[67]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients from 10 SEER registries</td><td align="left" rowspan="1" colspan="1">1985&#x02013;1993</td><td align="left" rowspan="1" colspan="1">Median income in zip code of residence (lowest quartile compared to highest 3)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">65&#x02013;75+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, SEER area</td><td align="left" rowspan="1" colspan="1">OR of surgery for black v white, univariable rates of surgery used here</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Earle et al, 2002 <xref rid="pmed.1001376-Earle2" ref-type="bibr">[68]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients from 11 SEER registries</td><td align="left" rowspan="1" colspan="1">1991&#x02013;1996</td><td align="left" rowspan="1" colspan="1">Census tract median household income</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">any time</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, year of diagnosis, teaching hospital, seen by oncologist, SEER area</td><td align="left" rowspan="1" colspan="1">SEP non sig in multivariable analysis but only univariable rate shown.</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Lathan et al, 2006 <xref rid="pmed.1001376-Lathan2" ref-type="bibr">[69]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients from 11 SEER registries</td><td align="left" rowspan="1" colspan="1">1991&#x02013;1999</td><td align="left" rowspan="1" colspan="1">Census tract median household income</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">65+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, SEER region, teaching hospital, rural/urban</td><td align="left" rowspan="1" colspan="1">Quality issues</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Ou et al, 2008 <xref rid="pmed.1001376-Ou1" ref-type="bibr">[70]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">California Cancer Registry (part of SEER)</td><td align="left" rowspan="1" colspan="1">California</td><td align="left" rowspan="1" colspan="1">1989&#x02013;2003</td><td align="left" rowspan="1" colspan="1">Composite measure (7 indicators of education, income and occupation)</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">0&#x02013;89</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Ethnicity, tumour grade, tumour location, histologic grade, marital status</td><td align="left" rowspan="1" colspan="1">SEP not reported in multivariable analysis. Univariable rate shown.</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Suga et al, 2010 <xref rid="pmed.1001376-Suga1" ref-type="bibr">[71]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">California Cancer Registry</td><td align="left" rowspan="1" colspan="1">Sacramento region in Northern California</td><td align="left" rowspan="1" colspan="1">1994&#x02013;2004</td><td align="left" rowspan="1" colspan="1">Census tract composite variable income, education, employment, poverty, rent, housing value</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Ethnicity, residence (urban/rural)</td><td align="left" rowspan="1" colspan="1">No CIs</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Tammemagi et al, 2004 <xref rid="pmed.1001376-Tammemagi1" ref-type="bibr">[72]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Josephine Ford Cancer Center Tumor Registry</td><td align="left" rowspan="1" colspan="1">Detroit (receiving care at Henry Ford Health System)</td><td align="left" rowspan="1" colspan="1">1995&#x02013;1998</td><td align="left" rowspan="1" colspan="1">Census tract median household income</td><td align="left" rowspan="1" colspan="1">Contin-uous<xref ref-type="table-fn" rid="nt113">a</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, marital status, smoking history, alcohol use, drug use</td><td align="left" rowspan="1" colspan="1">SEP not reported in multivariable analysis. Univariable OR shown.</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Wang et al, 2008 <xref rid="pmed.1001376-Wang1" ref-type="bibr">[73]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">SEER cancer registry linked to Medicare data</td><td align="left" rowspan="1" colspan="1">Medicare patients 11 SEER registries</td><td align="left" rowspan="1" colspan="1">1992&#x02013;2002</td><td align="left" rowspan="1" colspan="1">% below census tract poverty level</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">4 months</td><td align="left" rowspan="1" colspan="1">66&#x02013;85</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Co-morbidity, ethnicity, year of diagnosis, grade, SEER region, census tract education, marital status, teaching hospital, radiation</td><td align="left" rowspan="1" colspan="1">SEP not reported in multivariable analysis.OR for consultation but not treatment shown.</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Yang et al, 2010 <xref rid="pmed.1001376-Yang1" ref-type="bibr">[74]</xref>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Florida Cancer registry linked to inpatient and outpatient medical records</td><td align="left" rowspan="1" colspan="1">Florida</td><td align="left" rowspan="1" colspan="1">1998&#x02013;2002</td><td align="left" rowspan="1" colspan="1">Census tract poverty level</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">&#x0003c;45&#x02013;70+</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Univariable analysis only</td><td align="left" rowspan="1" colspan="1">Univariable rate</td><td align="left" rowspan="1" colspan="1">2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt112"><label/><p>Quality scores range from 1 (lowest quality) to 6 (highest quality).</p></fn><fn id="nt113"><label>a</label><p>Odds ratio for increase per $10,000 income.</p></fn><fn id="nt114"><label/><p>CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; SEER, National Cancer Institute's Surveillance, Epidemiology and End Results database; SEP, socioeconomic position.</p></fn></table-wrap-foot></table-wrap><p>An individual measure of SEP (education level) was used in one study <xref rid="pmed.1001376-Berglund1" ref-type="bibr">[19]</xref>. All other studies used area-level measures of deprivation, income, poverty, or education level.</p><p>In terms of quality, the non-UHCS studies that carried out multivariable analyses had better control for confounding than did UHCS studies, as they tended to stratify by stage and histology. However, half of the non-UHCS papers used a Medicare-only population aged over 65, and so were more restrictive in population terms than the UHCS studies.</p><p>Twenty-nine papers met the criteria for meta-analysis&#x02014;19 from UHCSs and 10 from non-UHCSs. However, six studies that examined receipt of treatment in low compared to high SEP presented the results as a single OR and so could not be included in the meta-analyses. Seventeen studies were included in the final meta-analyses and a further six in the sensitivity meta-analyses.</p></sec><sec id="s3b"><title>Surgery</title><p>Thirty-one papers (29 study populations) included receipt of surgery as an outcome&#x02014;18 UHCS papers (15 study populations) and 13 non-UHCS papers (14 study populations) (<xref ref-type="table" rid="pmed-1001376-t005">Tables 5</xref> and <xref ref-type="table" rid="pmed-1001376-t006">6</xref>). Of the papers that reported measures of significance (CIs or p-values), 20 out of 27 (74%) reported that lower SEP was significantly associated with lower likelihood of surgery when comparing the lowest with the highest SEP group, although three of these 20 papers did not find a significant trend across groups.</p><table-wrap id="pmed-1001376-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t005</object-id><label>Table 5</label><caption><title>Likelihood of receipt of surgery by SEP group (universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t005-5" xlink:href="pmed.1001376.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Surgery</td><td align="left" rowspan="1" colspan="1">Cohort No./No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">p-Value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-Analysis</td><td align="left" rowspan="1" colspan="1">Further Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bendzsak et al, 2011 <xref rid="pmed.1001376-Bendzsak1" ref-type="bibr">[49]</xref>
</td><td align="left" rowspan="1" colspan="1">1220</td><td align="left" rowspan="1" colspan="1">6499</td><td align="left" rowspan="1" colspan="1">18.77</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">21.1</td><td align="left" rowspan="1" colspan="1">18.3</td><td align="left" rowspan="1" colspan="1">19.7</td><td align="left" rowspan="1" colspan="1">18.8</td><td align="left" rowspan="1" colspan="1">16.8</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Campbell et al, 2002 <xref rid="pmed.1001376-Campbell1" ref-type="bibr">[35]</xref>
</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">653</td><td align="left" rowspan="1" colspan="1">13.02</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.76 (0.28 to 2.09)</td><td align="left" rowspan="1" colspan="1">0.70 (0.27 to 1.84)</td><td align="left" rowspan="1" colspan="1">0.88 (0.35 to 2.22)</td><td align="left" rowspan="1" colspan="1">0.59 (0.23 to 1.53)</td><td align="left" rowspan="1" colspan="1">0.423</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">P for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Hui et al, 2005 <xref rid="pmed.1001376-Hui1" ref-type="bibr">[51]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">526</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2003 <xref rid="pmed.1001376-Jack1" ref-type="bibr">[39]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">32818</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.98 (0.95 to 1.01)</td><td align="left" rowspan="1" colspan="1">0.7759</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2006 <xref rid="pmed.1001376-Jack2" ref-type="bibr">[40]</xref>
</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">695</td><td align="left" rowspan="1" colspan="1">6.04</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.82 (0.33 to 2.07)</td><td align="left" rowspan="1" colspan="1">0.89 (0.35 to 2.25)</td><td align="left" rowspan="1" colspan="1">0.16 (0.03 to 0.73)</td><td align="left" rowspan="1" colspan="1">0.75 (0.27 to 2.09)</td><td align="left" rowspan="1" colspan="1">0.1326</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Subset of Jack et al (2003) pop, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Jones et al,2008 <xref rid="pmed.1001376-Jones1" ref-type="bibr">[41]</xref>
</td><td align="left" rowspan="1" colspan="1">3552</td><td align="left" rowspan="1" colspan="1">34923</td><td align="left" rowspan="1" colspan="1">10.17</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.99 (0.99 to 1.00)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pollock &#x00026;Vickers, 1998 <xref rid="pmed.1001376-Pollock1" ref-type="bibr">[44]</xref>
</td><td align="left" rowspan="1" colspan="1">2869</td><td align="left" rowspan="1" colspan="1">38668</td><td align="left" rowspan="1" colspan="1">7.42</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.83 (0.69 to 1.00)</td><td align="left" rowspan="1" colspan="1">0.73 (0.61 to 0.88)</td><td align="left" rowspan="1" colspan="1">0.82 (0.68 to 0.98)</td><td align="left" rowspan="1" colspan="1">0.58 (0.48 to 0.70)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Hospital population, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Raine et al, 2010 <xref rid="pmed.1001376-Raine1" ref-type="bibr">[45]</xref>
</td><td align="left" rowspan="1" colspan="1">8790</td><td align="left" rowspan="1" colspan="1">36902</td><td align="left" rowspan="1" colspan="1">23.82</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.63 (1.49 to 1.77)</td><td align="left" rowspan="1" colspan="1">1.58 (1.46 to 1.72)</td><td align="left" rowspan="1" colspan="1">1.45 (1.35 to 1.57)</td><td align="left" rowspan="1" colspan="1">1.34 (1.25 to 1.45)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Elective admission population</td></tr><tr><td align="left" rowspan="1" colspan="1">Raine et al, 2010 <xref rid="pmed.1001376-Raine1" ref-type="bibr">[45]</xref>
</td><td align="left" rowspan="1" colspan="1">8923</td><td align="left" rowspan="1" colspan="1">186741</td><td align="left" rowspan="1" colspan="1">4.78</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">5.5</td><td align="left" rowspan="1" colspan="1">5.2</td><td align="left" rowspan="1" colspan="1">4.8</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">All admissions, univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Battersby et al, 2004 <xref rid="pmed.1001376-Battersby1" ref-type="bibr">[48]</xref>
</td><td align="left" rowspan="1" colspan="1">387</td><td align="left" rowspan="1" colspan="1">4092</td><td align="left" rowspan="1" colspan="1">9.46</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02212;0.10 (&#x02212;0.55 to 0.40)</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Rate by sex correlated with deprivation score (men), with overall treatment rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Battersby et al, 2004 <xref rid="pmed.1001376-Battersby1" ref-type="bibr">[48]</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02212;0.16 (&#x02212;0.59 to 0.35)</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Rate by sex correlated with deprivation score (women)</td></tr><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2010 <xref rid="pmed.1001376-Berglund1" ref-type="bibr">[19]</xref>
</td><td align="left" rowspan="1" colspan="1">626</td><td align="left" rowspan="1" colspan="1">3369</td><td align="left" rowspan="1" colspan="1">18.58</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.93 (1.25 to 3.00)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.33 (0.98 to 1.81)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2010 <xref rid="pmed.1001376-Berglund1" ref-type="bibr">[19]</xref>
</td><td align="left" rowspan="1" colspan="1">534</td><td align="left" rowspan="1" colspan="1">932</td><td align="left" rowspan="1" colspan="1">57.30</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">2.84 (1.40 to 5.79)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.53 (1.01 to 2.31)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">Early stage only - stage IA-IIB</td></tr><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2012 <xref rid="pmed.1001376-Berglund2" ref-type="bibr">[22]</xref>
</td><td align="left" rowspan="1" colspan="1">899</td><td align="left" rowspan="1" colspan="1">1826</td><td align="left" rowspan="1" colspan="1">49.18</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.74 (0.51 to 1.06)</td><td align="left" rowspan="1" colspan="1">0.71 (0.49 to 1.02)</td><td align="left" rowspan="1" colspan="1">0.73 (0.52 to 1.03)</td><td align="left" rowspan="1" colspan="1">0.67 (0.48 to 0.95)</td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Early stage only &#x02013; stage IA-IIB, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Cartman et al, 2002 <xref rid="pmed.1001376-Cartman1" ref-type="bibr">[50]</xref>
</td><td align="left" rowspan="1" colspan="1">2401</td><td align="left" rowspan="1" colspan="1">12570</td><td align="left" rowspan="1" colspan="1">19.10</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">19.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18.6</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Crawford et al, 2009 <xref rid="pmed.1001376-Crawford1" ref-type="bibr">[36]</xref>
</td><td align="left" rowspan="1" colspan="1">3335</td><td align="left" rowspan="1" colspan="1">18324</td><td align="left" rowspan="1" colspan="1">18.20</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.90 (0.81 to 1.00)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.82 (0.74 to 0.91)</td><td align="left" rowspan="1" colspan="1">0.80 (0.72 to 0.89)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05, &#x0003c;0.01, &#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Individual P values reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Mahmud et al, 2003 <xref rid="pmed.1001376-Mahmud1" ref-type="bibr">[42]</xref>
</td><td align="left" rowspan="1" colspan="1">866</td><td align="left" rowspan="1" colspan="1">4451</td><td align="left" rowspan="1" colspan="1">19.46</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">19.8</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21.0</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">McMahon et al, 2011 <xref rid="pmed.1001376-McMahon1" ref-type="bibr">[43]</xref>
</td><td align="left" rowspan="1" colspan="1">2374</td><td align="left" rowspan="1" colspan="1">18813</td><td align="left" rowspan="1" colspan="1">12.62</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.95 (0.83 to 1.09)</td><td align="left" rowspan="1" colspan="1">0.95 (0.83 to 1.08)</td><td align="left" rowspan="1" colspan="1">0.90 (0.79 to 1.03)</td><td align="left" rowspan="1" colspan="1">0.78 (0.65 to 0.94)</td><td align="left" rowspan="1" colspan="1">0.018</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">P for trend</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.96 (0.93 to 0.99)</td><td align="left" rowspan="1" colspan="1">0.018</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Paper presents results in 2 different ways</td></tr><tr><td align="left" rowspan="1" colspan="1">Riaz et al, 2012 <xref rid="pmed.1001376-Riaz1" ref-type="bibr">[34]</xref>
</td><td align="left" rowspan="1" colspan="1">6900</td><td align="left" rowspan="1" colspan="1">77349</td><td align="left" rowspan="1" colspan="1">8.92</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.88 (0.80 to 0.96)</td><td align="left" rowspan="1" colspan="1">0.91 (0.83 to 0.99)</td><td align="left" rowspan="1" colspan="1">0.82 (0.76 to 0.89)</td><td align="left" rowspan="1" colspan="1">0.76 (0.70 to 0.83)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">P for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Rich et al, 2011(1) <xref rid="pmed.1001376-Rich2" ref-type="bibr">[46]</xref>
</td><td align="left" rowspan="1" colspan="1">3427</td><td align="left" rowspan="1" colspan="1">24175</td><td align="left" rowspan="1" colspan="1">14.18</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.13 (0.98 to 1.32)</td><td align="left" rowspan="1" colspan="1">1.18 (1.02 to 1.37)</td><td align="left" rowspan="1" colspan="1">1.01 (0.87 to 1.16)</td><td align="left" rowspan="1" colspan="1">1.11 (0.96 to 1.27)</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">Subset of Rich et al 2011 (2) pop, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Rich et al, 2011(2) <xref rid="pmed.1001376-Rich1" ref-type="bibr">[21]</xref>
</td><td align="left" rowspan="1" colspan="1">4481</td><td align="left" rowspan="1" colspan="1">34436</td><td align="left" rowspan="1" colspan="1">13.01</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.99 (0.88 to 1.11)</td><td align="left" rowspan="1" colspan="1">1.04 (0.92 to 1.19)</td><td align="left" rowspan="1" colspan="1">0.98 (0.84 to 1.13)</td><td align="left" rowspan="1" colspan="1">0.86 (0.71 to 1.04)</td><td align="left" rowspan="1" colspan="1">0.132</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">P for trend</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt115"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position, Q5, low socioeconomic position.</p></fn><fn id="nt116"><label/><p>CI, confidence interval; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position; UHCS, universal health care system.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pmed-1001376-t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t006</object-id><label>Table 6</label><caption><title>Likelihood of receipt of surgery by SEP group (non-universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t006-6" xlink:href="pmed.1001376.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Surgery</td><td align="left" rowspan="1" colspan="1">Cohort No./No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">Stage(s) Included</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">p-Value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-Analysis</td><td align="left" rowspan="1" colspan="1">Further Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bradley et al, 2008 <xref rid="pmed.1001376-Bradley1" ref-type="bibr">[57]</xref>
</td><td align="left" rowspan="1" colspan="1">1336</td><td align="left" rowspan="1" colspan="1">2626</td><td align="left" rowspan="1" colspan="1">50.88</td><td align="left" rowspan="1" colspan="1">I,II,IIIa</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.80 (0.67 to 0.98)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Esnoala et al, 2008 <xref rid="pmed.1001376-Esnaola1" ref-type="bibr">[60]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2791</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">local</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.67 (0.51 to 0.88)</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Greenwald et al, 1998 <xref rid="pmed.1001376-Greenwald1" ref-type="bibr">[61]</xref>
</td><td align="left" rowspan="1" colspan="1">3053</td><td align="left" rowspan="1" colspan="1">5157</td><td align="left" rowspan="1" colspan="1">59.20</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.076</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">SE&#x0200a;=&#x0200a;0.011 (no CIs shown)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hardy et al, 2009 <xref rid="pmed.1001376-Hardy1" ref-type="bibr">[62]</xref>
</td><td align="left" rowspan="1" colspan="1">11834</td><td align="left" rowspan="1" colspan="1">19658</td><td align="left" rowspan="1" colspan="1">60.20</td><td align="left" rowspan="1" colspan="1">I,II</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.92 (0.84 to 1.14)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.78 (0.75 to 1.03)</td><td align="left" rowspan="1" colspan="1">0.68 (0.60 to 0.77)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05, &#x0003e;0.05, &#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Individual p values reported corrected OR supplied<xref ref-type="table-fn" rid="nt118">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Lathan et al, 2008 <xref rid="pmed.1001376-Lathan1" ref-type="bibr">[64]</xref>
</td><td align="left" rowspan="1" colspan="1">4563</td><td align="left" rowspan="1" colspan="1">9688</td><td align="left" rowspan="1" colspan="1">47.10</td><td align="left" rowspan="1" colspan="1">I,II,III</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.06 (1.02 to 1.11)</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Subset of Lathan et al (2006) pop</td></tr><tr><td align="left" rowspan="1" colspan="1">Ou et al, 2008 <xref rid="pmed.1001376-Ou1" ref-type="bibr">[70]</xref>
</td><td align="left" rowspan="1" colspan="1">16185</td><td align="left" rowspan="1" colspan="1">19700</td><td align="left" rowspan="1" colspan="1">82.16</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">86.9</td><td align="left" rowspan="1" colspan="1">84.8</td><td align="left" rowspan="1" colspan="1">81.1</td><td align="left" rowspan="1" colspan="1">79.6</td><td align="left" rowspan="1" colspan="1">74.5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smith et al, 1995 <xref rid="pmed.1001376-Smith1" ref-type="bibr">[66]</xref>
</td><td align="left" rowspan="1" colspan="1">801</td><td align="left" rowspan="1" colspan="1">2813</td><td align="left" rowspan="1" colspan="1">28.47</td><td align="left" rowspan="1" colspan="1">local</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.04 (0.90 to 1.19)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.001</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tammemagi et al, 2004 <xref rid="pmed.1001376-Tammemagi1" ref-type="bibr">[72]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">1155</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">I,II</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.19 (1.03 to 1.30)</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable OR</td></tr><tr><td align="left" rowspan="1" colspan="1">Bach et al, 1999 <xref rid="pmed.1001376-Bach1" ref-type="bibr">[67]</xref>
</td><td align="left" rowspan="1" colspan="1">550</td><td align="left" rowspan="1" colspan="1">860</td><td align="left" rowspan="1" colspan="1">63.95</td><td align="left" rowspan="1" colspan="1">I,II</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">67.5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">61.9</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Surgery (blacks)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bach et al, 1999 <xref rid="pmed.1001376-Bach1" ref-type="bibr">[67]</xref>
</td><td align="left" rowspan="1" colspan="1">7763</td><td align="left" rowspan="1" colspan="1">10124</td><td align="left" rowspan="1" colspan="1">76.68</td><td align="left" rowspan="1" colspan="1">I,II</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">78.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">70.7</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Surgery (whites)</td></tr><tr><td align="left" rowspan="1" colspan="1">Polednak, 2001 <xref rid="pmed.1001376-Polednak1" ref-type="bibr">[65]</xref>
</td><td align="left" rowspan="1" colspan="1">1385</td><td align="left" rowspan="1" colspan="1">1564</td><td align="left" rowspan="1" colspan="1">88.55</td><td align="left" rowspan="1" colspan="1">I,II</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.27 (0.74 to 2.18)</td><td align="left" rowspan="1" colspan="1">1.15 (0.65 to 2.03)</td><td align="left" rowspan="1" colspan="1">1.17 (0.67 to 2.04)</td><td align="left" rowspan="1" colspan="1">1.78 (1.05 to 3.01)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05, &#x0003e;0.05, &#x0003e;0.05, &#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Odds of not receiving surgery, individual p values reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Smith et al, 1995 <xref rid="pmed.1001376-Smith1" ref-type="bibr">[66]</xref>
</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">2396</td><td align="left" rowspan="1" colspan="1">2.38</td><td align="left" rowspan="1" colspan="1">distant</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.27 (0.97 to 1.67)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.001</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Suga et al, 2010 <xref rid="pmed.1001376-Suga1" ref-type="bibr">[71]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">12395</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Surgery after invasive staging, no CIs</td></tr><tr><td align="left" rowspan="1" colspan="1">Suga et al, 2010 <xref rid="pmed.1001376-Suga1" ref-type="bibr">[71]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">12395</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Surgery after non-invasive staging, no CIs</td></tr><tr><td align="left" rowspan="1" colspan="1">Lathan et al, 2006 <xref rid="pmed.1001376-Lathan2" ref-type="bibr">[69]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">14224</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.05 (1.02 to 1.08)</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yang et al, 2010 <xref rid="pmed.1001376-Yang1" ref-type="bibr">[74]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">all</td><td align="left" rowspan="1" colspan="1">all</td><td align="left" rowspan="1" colspan="1">24.6</td><td align="left" rowspan="1" colspan="1">22.2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20.7</td><td align="left" rowspan="1" colspan="1">18.3</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt117"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.</p></fn><fn id="nt118"><label>a</label><p>We are grateful to the authors for supplying a corrected OR to allow inclusion of this study in the meta-analysis.</p></fn><fn id="nt119"><label/><p>CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SE, standard error; SEP, socioeconomic position.</p></fn></table-wrap-foot></table-wrap><p>Meta-analysis of all 16 populations that were suitable for inclusion showed a significant negative effect of lower SEP on the likelihood of receiving surgery: OR&#x0200a;=&#x0200a;0.72 (95% CI 0.65 to 0.80), p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;80% (<xref ref-type="supplementary-material" rid="pmed.1001376.s001">Figure S1</xref>). Including only non-overlapping study populations (n&#x0200a;=&#x0200a;12) gave a similar result: OR&#x0200a;=&#x0200a;0.68 (95% CI 0.63 to 0.75), p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;53% (<xref ref-type="fig" rid="pmed-1001376-g002">Figure 2</xref>). Similar results were also seen for the subgroup of eight papers including NSCLC patients only (OR&#x0200a;=&#x0200a;0.73 [95% CI 0.68 to 0.80] p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;24%) (<xref ref-type="supplementary-material" rid="pmed.1001376.s002">Figure S2</xref>) and with further stratification by health care system; NSCLC (UHCS): OR&#x0200a;=&#x0200a;0.75 (95% CI 0.66 to 0.85), p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;29%; NSCLC (non-UHCS, early stage only, co-morbidity included): OR&#x0200a;=&#x0200a;0.71 (95% CI 0.64 to 0.78) p&#x0003c;0.001; I<sup>2</sup>&#x0200a;=&#x0200a;2% (<xref ref-type="fig" rid="pmed-1001376-g002">Figure 2</xref>).</p><fig id="pmed-1001376-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.g002</object-id><label>Figure 2</label><caption><title>Meta-analysis of odds of receipt of surgery in low versus high SEP.</title><p>CI, confidence interval; non-UHCS, non-universal health care system; NSCLC, non-small cell lung cancer; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.</p></caption><graphic xlink:href="pmed.1001376.g002"/></fig><p>Lower SEP was associated with a lower likelihood of receiving lung cancer surgery, in both types of health care system, and in studies where histology and stage at diagnosis were taken into account.</p></sec><sec id="s3c"><title>Chemotherapy</title><p>Twenty-three papers included chemotherapy as an outcome&#x02014;14 UHCS papers (12 populations) and nine non-UHCS papers (10 populations) (<xref ref-type="table" rid="pmed-1001376-t007">Tables 7</xref> and <xref ref-type="table" rid="pmed-1001376-t008">8</xref>). Of the 21 papers that reported measures of significance, 15 (71%) reported that lower SEP was significantly associated with lower likelihood of receipt of chemotherapy.</p><table-wrap id="pmed-1001376-t007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t007</object-id><label>Table 7</label><caption><title>Likelihood of receipt of chemotherapy by SEP group (universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t007-7" xlink:href="pmed.1001376.t007"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Chemo</td><td align="left" rowspan="1" colspan="1">Cohort No./No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">p-Value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-Analysis</td><td align="left" rowspan="1" colspan="1">Further Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2012 <xref rid="pmed.1001376-Berglund2" ref-type="bibr">[22]</xref>
</td><td align="left" rowspan="1" colspan="1">3661</td><td align="left" rowspan="1" colspan="1">10039</td><td align="left" rowspan="1" colspan="1">36.47</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.90 (0.77 to 1.06)</td><td align="left" rowspan="1" colspan="1">0.78 (0.67 to 0.91)</td><td align="left" rowspan="1" colspan="1">0.77 (0.66 to 0.89)</td><td align="left" rowspan="1" colspan="1">0.75 (0.65 to 0.87)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">NSCLC stage IIIA-IV &#x00026; all stage SCLC, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Campbell et al, 2002 <xref rid="pmed.1001376-Campbell1" ref-type="bibr">[35]</xref>
</td><td align="left" rowspan="1" colspan="1">124</td><td align="left" rowspan="1" colspan="1">653</td><td align="left" rowspan="1" colspan="1">18.99</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.58 (0.21 to 1.57)</td><td align="left" rowspan="1" colspan="1">0.72 (0.29 to 1.78)</td><td align="left" rowspan="1" colspan="1">0.41 (0.16 to 1.05)</td><td align="left" rowspan="1" colspan="1">0.39 (0.16 to 0.96)</td><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2003 <xref rid="pmed.1001376-Jack1" ref-type="bibr">[39]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">32818</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.96 (0.94 to 0.98)</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Subset of Patel et al (2007) pop</td></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2006 <xref rid="pmed.1001376-Jack2" ref-type="bibr">[40]</xref>
</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">695</td><td align="left" rowspan="1" colspan="1">15.54</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.04 (0.50 to 2.16)</td><td align="left" rowspan="1" colspan="1">0.81 (0.38 to 1.70)</td><td align="left" rowspan="1" colspan="1">0.89 (0.43 to 1.85)</td><td align="left" rowspan="1" colspan="1">1.04 (0.48 to 2.25)</td><td align="left" rowspan="1" colspan="1">0.9130</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Subset of Patel et al (2007) pop, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Jones et al,2008 <xref rid="pmed.1001376-Jones1" ref-type="bibr">[41]</xref>
</td><td align="left" rowspan="1" colspan="1">5783</td><td align="left" rowspan="1" colspan="1">34923</td><td align="left" rowspan="1" colspan="1">16.56</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.99 (0.99 to 0.99)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Patel et al, 2007 <xref rid="pmed.1001376-Patel1" ref-type="bibr">[54]</xref>
</td><td align="left" rowspan="1" colspan="1">11217</td><td align="left" rowspan="1" colspan="1">67312</td><td align="left" rowspan="1" colspan="1">16.66</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">18.3</td><td align="left" rowspan="1" colspan="1">15.7</td><td align="left" rowspan="1" colspan="1">14.5</td><td align="left" rowspan="1" colspan="1">12.8</td><td align="left" rowspan="1" colspan="1">12.8</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Adjusted rates, no CIs</td></tr><tr><td align="left" rowspan="1" colspan="1">Rich et al, 2011(1) <xref rid="pmed.1001376-Rich2" ref-type="bibr">[46]</xref>
</td><td align="left" rowspan="1" colspan="1">14168</td><td align="left" rowspan="1" colspan="1">59592</td><td align="left" rowspan="1" colspan="1">23.78</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.97 (0.90 to 1.04)</td><td align="left" rowspan="1" colspan="1">0.89 (0.83 to 0.96)</td><td align="left" rowspan="1" colspan="1">0.83 (0.77 to 0.89)</td><td align="left" rowspan="1" colspan="1">0.85 (0.79 to 0.91)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hui et al, 2005 <xref rid="pmed.1001376-Hui1" ref-type="bibr">[51]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">526</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2010 <xref rid="pmed.1001376-Berglund1" ref-type="bibr">[19]</xref>
</td><td align="left" rowspan="1" colspan="1">1285</td><td align="left" rowspan="1" colspan="1">3369</td><td align="left" rowspan="1" colspan="1">38.14</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.35 (1.00 to 1.81)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.25 (1.03 to 1.52)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pagano et al, 2010 <xref rid="pmed.1001376-Pagano1" ref-type="bibr">[53]</xref>
</td><td align="left" rowspan="1" colspan="1">430</td><td align="left" rowspan="1" colspan="1">1231</td><td align="left" rowspan="1" colspan="1">34.93</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.98 (0.64 to 1.50)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.63 (1.08 to 2.44)</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Odds of receiving chemo +/or radio rather than surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">Younis et al, 2008 <xref rid="pmed.1001376-Younis1" ref-type="bibr">[56]</xref>
</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">26.85</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">4.7 (1.3 to 17.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.015</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Odds of referral for adjuvant chemo after surgery, stage I, II, III</td></tr><tr><td align="left" rowspan="1" colspan="1">Cartman et al, 2002 <xref rid="pmed.1001376-Cartman1" ref-type="bibr">[50]</xref>
</td><td align="left" rowspan="1" colspan="1">1349</td><td align="left" rowspan="1" colspan="1">2448</td><td align="left" rowspan="1" colspan="1">55.11</td><td align="left" rowspan="1" colspan="1">SCLC</td><td align="left" rowspan="1" colspan="1">52.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">56.8</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Crawford et al, 2009 <xref rid="pmed.1001376-Crawford1" ref-type="bibr">[36]</xref>
</td><td align="left" rowspan="1" colspan="1">3619</td><td align="left" rowspan="1" colspan="1">5510</td><td align="left" rowspan="1" colspan="1">65.68</td><td align="left" rowspan="1" colspan="1">SCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.10 (0.94 to 1.30)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.91 (0.78 to 1.08)</td><td align="left" rowspan="1" colspan="1">0.94 (0.80 to 1.11)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Individual p-values, all reported as &#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Mahmud et al, 2003 <xref rid="pmed.1001376-Mahmud1" ref-type="bibr">[42]</xref>
</td><td align="left" rowspan="1" colspan="1">425</td><td align="left" rowspan="1" colspan="1">1002</td><td align="left" rowspan="1" colspan="1">42.42</td><td align="left" rowspan="1" colspan="1">SCLC</td><td align="left" rowspan="1" colspan="1">37.8</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">40.5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50.2</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt120"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.</p></fn><fn id="nt121"><label/><p>CI, confidence interval; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position; UHCS, universal health care system.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pmed-1001376-t008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t008</object-id><label>Table 8</label><caption><title>Likelihood of receipt of chemotherapy by SEP group (non-universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t008-8" xlink:href="pmed.1001376.t008"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Chemo</td><td align="left" rowspan="1" colspan="1">Cohort No./No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">Stage</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">p-Value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-Analysis</td><td align="left" rowspan="1" colspan="1">Further Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bradley et al, 2008 <xref rid="pmed.1001376-Bradley1" ref-type="bibr">[57]</xref>
</td><td align="left" rowspan="1" colspan="1">643</td><td align="left" rowspan="1" colspan="1">2348</td><td align="left" rowspan="1" colspan="1">27.39</td><td align="left" rowspan="1" colspan="1">I,II, IIIa</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.09 (0.87 to 1.37)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hardy et al, 2009 <xref rid="pmed.1001376-Hardy1" ref-type="bibr">[62]</xref>
</td><td align="left" rowspan="1" colspan="1">2951</td><td align="left" rowspan="1" colspan="1">19658</td><td align="left" rowspan="1" colspan="1">15.01</td><td align="left" rowspan="1" colspan="1">I, II</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.91 (0.81 to 1.02)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.96 (0.85 to 1.09)</td><td align="left" rowspan="1" colspan="1">0.85 (0.74 to 0.98)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05, &#x0003e;0.05, &#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Individual p-values reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Ou et al, 2008 <xref rid="pmed.1001376-Ou1" ref-type="bibr">[70]</xref>
</td><td align="left" rowspan="1" colspan="1">1175</td><td align="left" rowspan="1" colspan="1">19700</td><td align="left" rowspan="1" colspan="1">5.96</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">7.4</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td></tr><tr><td align="left" rowspan="1" colspan="1">Davidoff et al, 2010 <xref rid="pmed.1001376-Davidoff1" ref-type="bibr">[58]</xref>
</td><td align="left" rowspan="1" colspan="1">5499</td><td align="left" rowspan="1" colspan="1">21285</td><td align="left" rowspan="1" colspan="1">25.84</td><td align="left" rowspan="1" colspan="1">IIIB, IV</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.43 (1.28 to 1.60)</td><td align="left" rowspan="1" colspan="1">1.17 (1.05 to 1.30)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.11 (1.00 to 1.22)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01, &#x0003c;0.01, &#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Individual p-values reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Earle et al, 2000 <xref rid="pmed.1001376-Earle1" ref-type="bibr">[59]</xref>
</td><td align="left" rowspan="1" colspan="1">1356</td><td align="left" rowspan="1" colspan="1">6308</td><td align="left" rowspan="1" colspan="1">21.50</td><td align="left" rowspan="1" colspan="1">IV</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.07 (1.02 to 1.12)</td><td align="left" rowspan="1" colspan="1">0.0077</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Subset of Earle (2002)</td></tr><tr><td align="left" rowspan="1" colspan="1">Earle et al, 2002 <xref rid="pmed.1001376-Earle2" ref-type="bibr">[68]</xref>
</td><td align="left" rowspan="1" colspan="1">8813</td><td align="left" rowspan="1" colspan="1">12015</td><td align="left" rowspan="1" colspan="1">73.35</td><td align="left" rowspan="1" colspan="1">IV</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable analysis only. SEP was included in multivariable analysis but non-sig (figs not reported)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hardy et al, 2009 <xref rid="pmed.1001376-Hardy1" ref-type="bibr">[62]</xref>
</td><td align="left" rowspan="1" colspan="1">26417</td><td align="left" rowspan="1" colspan="1">51243</td><td align="left" rowspan="1" colspan="1">51.55</td><td align="left" rowspan="1" colspan="1">III, IV</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.87 (0.78 to 0.96)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.76 (0.63 to 0.90)</td><td align="left" rowspan="1" colspan="1">0.60 (0.45 to 0.79)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05, &#x0003c;0.05, &#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">Individual p-values reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Tammemagi et al, 2004 <xref rid="pmed.1001376-Tammemagi1" ref-type="bibr">[72]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">1155</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">III,IV</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.09 (1.01 to 1.18)</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable OR</td></tr><tr><td align="left" rowspan="1" colspan="1">Davidoff et al, 2010 <xref rid="pmed.1001376-Davidoff1" ref-type="bibr">[58]</xref>
</td><td align="left" rowspan="1" colspan="1">749</td><td align="left" rowspan="1" colspan="1">1946</td><td align="left" rowspan="1" colspan="1">38.49</td><td align="left" rowspan="1" colspan="1">IIIB, IV</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">0.86(0.69 to 1.08)</td><td align="left" rowspan="1" colspan="1">0.96 (0.77 to 1.19)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.99 (0.81 to 1.22)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Odds of single agent compared to two-agent chemo.</td></tr><tr><td align="left" rowspan="1" colspan="1">Wang et al, 2008 <xref rid="pmed.1001376-Wang1" ref-type="bibr">[73]</xref>
</td><td align="left" rowspan="1" colspan="1">1521</td><td align="left" rowspan="1" colspan="1">3196</td><td align="left" rowspan="1" colspan="1">47.59</td><td align="left" rowspan="1" colspan="1">II, IIIa</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.08 (0.97 to 1.21)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.08 (0.97 to 1.21)</td><td align="left" rowspan="1" colspan="1">0.97 (0.85 to 1.10)</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Odds of receiving oncology consultation.</td></tr><tr><td align="left" rowspan="1" colspan="1">Yang et al, 2010 <xref rid="pmed.1001376-Yang1" ref-type="bibr">[74]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">32.2</td><td align="left" rowspan="1" colspan="1">30.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">29.9</td><td align="left" rowspan="1" colspan="1">30.1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt122"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.</p></fn><fn id="nt123"><label/><p>CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position.</p></fn></table-wrap-foot></table-wrap><p>Meta-analysis of the ten populations that were suitable for inclusion found a significant negative effect of lower SEP on the likelihood of receiving chemotherapy: OR&#x0200a;=&#x0200a;0.81 (95% CI 0.73 to 0.89), p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;68% (<xref ref-type="supplementary-material" rid="pmed.1001376.s003">Figure S3</xref>). Similarly, in a meta-analysis of the eight papers containing non-overlapping populations that were selected for inclusion, the odds of receiving chemotherapy were significantly lower for those with low SEP compared to those with high SEP (OR&#x0200a;=&#x0200a;0.82 [95% CI 0.72 to 0.93], p&#x0200a;=&#x0200a;0.003, I<sup>2</sup>&#x0200a;=&#x0200a;67%), overall. A similar pattern was found in UHCS (OR&#x0200a;=&#x0200a;0.80 [95% CI 0.68 to 0.95], p&#x0200a;=&#x0200a;0.01, I<sup>2</sup>&#x0200a;=&#x0200a;46%); and in non-UHCS settings (OR&#x0200a;=&#x0200a;0.85 [95% CI 0.68 to 1.07], p&#x0200a;=&#x0200a;0.16, I<sup>2</sup>&#x0200a;=&#x0200a;85%), although this did not reach significance (<xref ref-type="fig" rid="pmed-1001376-g003">Figure 3</xref>).</p><fig id="pmed-1001376-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.g003</object-id><label>Figure 3</label><caption><title>Meta-analysis of odds of receipt of chemotherapy in low versus high SEP.</title><p>CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.</p></caption><graphic xlink:href="pmed.1001376.g003"/></fig></sec><sec id="s3d"><title>Radiotherapy</title><p>Eighteen papers (18 populations) examined receipt of radiotherapy for lung cancer&#x02014;12 in UHCS settings (11 populations) and six in non-UHCS settings (seven populations) (<xref ref-type="table" rid="pmed-1001376-t009">Tables 9</xref> and <xref ref-type="table" rid="pmed-1001376-t010">10</xref>). Only one UHCS study found an association between SEP and receipt of radiotherapy. The non-UHCS studies had very heterogeneous outcomes.</p><table-wrap id="pmed-1001376-t009" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t009</object-id><label>Table 9</label><caption><title>Likelihood of receipt of radiotherapy by SEP group (universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t009-9" xlink:href="pmed.1001376.t009"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Radio</td><td align="left" rowspan="1" colspan="1">Cohort No./No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">p-Value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-Analysis</td><td align="left" rowspan="1" colspan="1">Further Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2012 <xref rid="pmed.1001376-Berglund2" ref-type="bibr">[22]</xref>
</td><td align="left" rowspan="1" colspan="1">1054</td><td align="left" rowspan="1" colspan="1">2771</td><td align="left" rowspan="1" colspan="1">38.04</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.16 (0.88 to 1.54)</td><td align="left" rowspan="1" colspan="1">1.17 (0.90 to 1.53)</td><td align="left" rowspan="1" colspan="1">1.18 (0.91 to 1.53)</td><td align="left" rowspan="1" colspan="1">0.99 (0.77 to 1.29)</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Stage III only, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Campbell et al, 2002 <xref rid="pmed.1001376-Campbell1" ref-type="bibr">[35]</xref>
</td><td align="left" rowspan="1" colspan="1">412</td><td align="left" rowspan="1" colspan="1">653</td><td align="left" rowspan="1" colspan="1">63.09</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1,00</td><td align="left" rowspan="1" colspan="1">2.08 (1.11 to 3.91)</td><td align="left" rowspan="1" colspan="1">2.27 (1.24 to 4.16)</td><td align="left" rowspan="1" colspan="1">1.47 (0.83 to 2.60)</td><td align="left" rowspan="1" colspan="1">1.86 (1.05 to 3.28)</td><td align="left" rowspan="1" colspan="1">0.378</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">P for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2003 <xref rid="pmed.1001376-Jack1" ref-type="bibr">[39]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">32818</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00 (0.99 to 1.02)</td><td align="left" rowspan="1" colspan="1">0.2048</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2006 <xref rid="pmed.1001376-Jack2" ref-type="bibr">[40]</xref>
</td><td align="left" rowspan="1" colspan="1">338</td><td align="left" rowspan="1" colspan="1">695</td><td align="left" rowspan="1" colspan="1">48.63</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.24 (0.76 to 2.02)</td><td align="left" rowspan="1" colspan="1">0.76 (0.46 to 1.26)</td><td align="left" rowspan="1" colspan="1">0.98 (0.60 to 1.59)</td><td align="left" rowspan="1" colspan="1">0.68 (0.41 to 1.14)</td><td align="left" rowspan="1" colspan="1">0.0978</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Subset of Jack et al (2003) pop, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Jones et al,2008 <xref rid="pmed.1001376-Jones1" ref-type="bibr">[41]</xref>
</td><td align="left" rowspan="1" colspan="1">13857</td><td align="left" rowspan="1" colspan="1">34923</td><td align="left" rowspan="1" colspan="1">39.68</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.99 (0.99 to 1.00)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Rich et al, 2011(1) <xref rid="pmed.1001376-Rich2" ref-type="bibr">[46]</xref>
</td><td align="left" rowspan="1" colspan="1">12079</td><td align="left" rowspan="1" colspan="1">59592</td><td align="left" rowspan="1" colspan="1">20.27</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.08 (1.01 to 1.16)</td><td align="left" rowspan="1" colspan="1">1.12 (1.04 to 1.20)</td><td align="left" rowspan="1" colspan="1">1.12 (1.04 to 1.20)</td><td align="left" rowspan="1" colspan="1">1.02 (0.95 to 1.09)</td><td align="left" rowspan="1" colspan="1">0.80</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">P for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Hui et al, 2005 <xref rid="pmed.1001376-Hui1" ref-type="bibr">[51]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">526</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">0.84</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Stevens et al, 2009 <xref rid="pmed.1001376-Stevens3" ref-type="bibr">[55]</xref>
</td><td align="left" rowspan="1" colspan="1">222</td><td align="left" rowspan="1" colspan="1">555</td><td align="left" rowspan="1" colspan="1">40.00</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.8 (0.4 to 1.5)</td><td align="left" rowspan="1" colspan="1">0.6 (0.3 to 1.2)</td><td align="left" rowspan="1" colspan="1">0.9 (0.5 to 1.6)</td><td align="left" rowspan="1" colspan="1">0.7 (0.4 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Hosp pop, univariable OR</td></tr><tr><td align="left" rowspan="1" colspan="1">Berglund et al, 2010 <xref rid="pmed.1001376-Berglund1" ref-type="bibr">[19]</xref>
</td><td align="left" rowspan="1" colspan="1">863</td><td align="left" rowspan="1" colspan="1">3369</td><td align="left" rowspan="1" colspan="1">25.62</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">0.91 (0.67 to 1.22)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.12 (0.93 to 1.36)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Erridge et al, 2002 <xref rid="pmed.1001376-Erridge2" ref-type="bibr">[37]</xref>
</td><td align="left" rowspan="1" colspan="1">824</td><td align="left" rowspan="1" colspan="1">3177</td><td align="left" rowspan="1" colspan="1">25.94</td><td align="left" rowspan="1" colspan="1">NSCLC/unknown</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.94 (0.70 to 1.26)</td><td align="left" rowspan="1" colspan="1">1.04 (0.79 to 1.38)</td><td align="left" rowspan="1" colspan="1">1.33 (1.01 to 1.75)</td><td align="left" rowspan="1" colspan="1">1.13 (0.84 to 1.51)</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mahmud et al, 2003 <xref rid="pmed.1001376-Mahmud1" ref-type="bibr">[42]</xref>
</td><td align="left" rowspan="1" colspan="1">1265</td><td align="left" rowspan="1" colspan="1">4451</td><td align="left" rowspan="1" colspan="1">28.42</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">26.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">29.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">29.9</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr><tr><td align="left" rowspan="1" colspan="1">Cartman et al, 2002 <xref rid="pmed.1001376-Cartman1" ref-type="bibr">[50]</xref>
</td><td align="left" rowspan="1" colspan="1">693</td><td align="left" rowspan="1" colspan="1">2448</td><td align="left" rowspan="1" colspan="1">28.31</td><td align="left" rowspan="1" colspan="1">SCLC</td><td align="left" rowspan="1" colspan="1">37.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">39.5</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable rate</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt124"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.</p></fn><fn id="nt125"><label/><p>CI, confidence interval; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position; UHCS, universal health care system.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pmed-1001376-t010" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t010</object-id><label>Table 10</label><caption><title>Likelihood of receipt of radiotherapy by SEP group (non-universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t010-10" xlink:href="pmed.1001376.t010"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Radio</td><td align="left" rowspan="1" colspan="1">Cohort No./No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">Stage</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">P value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-analysis</td><td align="left" rowspan="1" colspan="1">Further information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bradley et al, 2008 <xref rid="pmed.1001376-Bradley1" ref-type="bibr">[57]</xref>
</td><td align="left" rowspan="1" colspan="1">950</td><td align="left" rowspan="1" colspan="1">2348</td><td align="left" rowspan="1" colspan="1">40.46</td><td align="left" rowspan="1" colspan="1">I,II,IIIa</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.97 (0.79 to 1.19)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ou et al, 2008 <xref rid="pmed.1001376-Ou1" ref-type="bibr">[70]</xref>
</td><td align="left" rowspan="1" colspan="1">2779</td><td align="left" rowspan="1" colspan="1">19700</td><td align="left" rowspan="1" colspan="1">14.11</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">11.7</td><td align="left" rowspan="1" colspan="1">12.6</td><td align="left" rowspan="1" colspan="1">14.7</td><td align="left" rowspan="1" colspan="1">16.5</td><td align="left" rowspan="1" colspan="1">16.6</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td></tr><tr><td align="left" rowspan="1" colspan="1">Smith et al, 1995 <xref rid="pmed.1001376-Smith1" ref-type="bibr">[66]</xref>
</td><td align="left" rowspan="1" colspan="1">1323</td><td align="left" rowspan="1" colspan="1">2813</td><td align="left" rowspan="1" colspan="1">47.03</td><td align="left" rowspan="1" colspan="1">local</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.95 (0.83 to 1.09)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.001</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hardy et al, 2009 <xref rid="pmed.1001376-Hardy1" ref-type="bibr">[62]</xref>
</td><td align="left" rowspan="1" colspan="1">43519</td><td align="left" rowspan="1" colspan="1">51243</td><td align="left" rowspan="1" colspan="1">84.93</td><td align="left" rowspan="1" colspan="1">III,IV</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.01 (0.96 to 1.07)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.93 (0.88 to 0.99)</td><td align="left" rowspan="1" colspan="1">0.88 (0.82 to 0.93)</td><td align="left" rowspan="1" colspan="1">0.05, &#x0003c;0.05, &#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Individual p-values reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Hayman et al, 2007 <xref rid="pmed.1001376-Hayman1" ref-type="bibr">[63]</xref>
</td><td align="left" rowspan="1" colspan="1">6436</td><td align="left" rowspan="1" colspan="1">11084</td><td align="left" rowspan="1" colspan="1">58.07</td><td align="left" rowspan="1" colspan="1">IV</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.48 (1.17 to 1.87)</td><td align="left" rowspan="1" colspan="1">1.50 (1.17 to 1.91)</td><td align="left" rowspan="1" colspan="1">1.32 (1.01 to 1.72)</td><td align="left" rowspan="1" colspan="1">1.25 (0.93 to 1.69)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smith et al, 1995 <xref rid="pmed.1001376-Smith1" ref-type="bibr">[66]</xref>
</td><td align="left" rowspan="1" colspan="1">1438</td><td align="left" rowspan="1" colspan="1">2396</td><td align="left" rowspan="1" colspan="1">60.02</td><td align="left" rowspan="1" colspan="1">distant</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00 (0.90 to 1.12)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.001</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yang et al, 2010 <xref rid="pmed.1001376-Yang1" ref-type="bibr">[74]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">??</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">32.0</td><td align="left" rowspan="1" colspan="1">32.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">31.4</td><td align="left" rowspan="1" colspan="1">33.1</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Univariable analysis</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt126"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.</p></fn><fn id="nt127"><label/><p>CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SE, standard error; SEP, socioeconomic position.</p></fn></table-wrap-foot></table-wrap><p>Overall, no association between SEP and receipt of radiotherapy was seen in the meta-analysis of the seven studies with non-overlapping populations selected for inclusion (OR&#x0200a;=&#x0200a;0.99 [95% CI 0.86 to 1.14], p&#x0200a;=&#x0200a;0.89, I<sup>2</sup>&#x0200a;=&#x0200a;54%) (<xref ref-type="fig" rid="pmed-1001376-g004">Figure 4</xref>), or when all nine studies were included (OR&#x0200a;=&#x0200a;0.95 [95% CI 0.85 to 1.06], p&#x0200a;=&#x0200a;0.40, I<sup>2</sup>&#x0200a;=&#x0200a;71%) (<xref ref-type="supplementary-material" rid="pmed.1001376.s004">Figure S4</xref>). A significant association was seen for non-UHCS studies but only two studies were included here, each looking at different stage patients. </p><fig id="pmed-1001376-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.g004</object-id><label>Figure 4</label><caption><title>Meta-analysis of odds of receipt of radiotherapy in low versus high SEP.</title><p>CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.</p></caption><graphic xlink:href="pmed.1001376.g004"/></fig></sec><sec id="s3e"><title>Treatment Type not Specified</title><p>Seven papers (eight study populations) examined receipt of unspecified treatment, and three papers considered receipt of unspecified curative treatment in three populations (<xref ref-type="table" rid="pmed-1001376-t011">Tables 11</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t013">13</xref>). In the meta-analysis of five non-overlapping studies, low SEP was associated with a lower likelihood of receiving unspecified treatment (OR&#x0200a;=&#x0200a;0.78 [95% CI 0.74 to 0.83], p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;0) (<xref ref-type="fig" rid="pmed-1001376-g005">Figure 5</xref>). This was also seen when studies with overlapping populations were included (OR&#x0200a;=&#x0200a;0.80 [95% CI 0.77 to 0.84], p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;17%) (<xref ref-type="supplementary-material" rid="pmed.1001376.s005">Figure S5</xref>).</p><fig id="pmed-1001376-g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.g005</object-id><label>Figure 5</label><caption><title>Meta-analysis of odds of receipt of unspecified treatment in low versus high SEP.</title><p>CI, confidence interval; OR, odds ratio; SE, standard error; SEP, socioeconomic position.</p></caption><graphic xlink:href="pmed.1001376.g005"/></fig><table-wrap id="pmed-1001376-t011" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t011</object-id><label>Table 11</label><caption><title>Likelihood of receipt of any type of unspecified treatment by SEP group (universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t011-11" xlink:href="pmed.1001376.t011"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Treatment</td><td align="left" rowspan="1" colspan="1">Cohort No./No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">p-Value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-Analysis</td><td align="left" rowspan="1" colspan="1">Further Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Crawford et al, 2009 <xref rid="pmed.1001376-Crawford1" ref-type="bibr">[36]</xref>
</td><td align="left" rowspan="1" colspan="1">19667</td><td align="left" rowspan="1" colspan="1">34923</td><td align="left" rowspan="1" colspan="1">56.32</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.91 (0.86 to 0.97)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.82(0.77 to 0.88)</td><td align="left" rowspan="1" colspan="1">0.79 (0.74 to 0.84)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Individual p-values, all reported as &#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Erridge et al, 2009 <xref rid="pmed.1001376-Erridge1" ref-type="bibr">[18]</xref>
</td><td align="left" rowspan="1" colspan="1">2186</td><td align="left" rowspan="1" colspan="1">3833</td><td align="left" rowspan="1" colspan="1">57.03</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.3 (1.1 to 1.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">Scottish population</td></tr><tr><td align="left" rowspan="1" colspan="1">Erridge et al, 2009 <xref rid="pmed.1001376-Erridge1" ref-type="bibr">[18]</xref>
</td><td align="left" rowspan="1" colspan="1">1372</td><td align="left" rowspan="1" colspan="1">2073</td><td align="left" rowspan="1" colspan="1">66.18</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.3 (1.1 to 1.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">Canadian population</td></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2003 <xref rid="pmed.1001376-Jack1" ref-type="bibr">[39]</xref>
</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">32818</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.98 (0.96 to 0.99)</td><td align="left" rowspan="1" colspan="1">0.0091</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Jack et al, 2006 <xref rid="pmed.1001376-Jack2" ref-type="bibr">[40]</xref>
</td><td align="left" rowspan="1" colspan="1">414</td><td align="left" rowspan="1" colspan="1">695</td><td align="left" rowspan="1" colspan="1">59.57</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.91 (0.53 to 1.55)</td><td align="left" rowspan="1" colspan="1">0.69 (0.40 to 1.19)</td><td align="left" rowspan="1" colspan="1">0.57 (0.34 to 0.97)</td><td align="left" rowspan="1" colspan="1">0.65 (0.37 to 1.13)</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Subset of Jack et al (2003) population, p for trend</td></tr><tr><td align="left" rowspan="1" colspan="1">Stevens et al, 2007 <xref rid="pmed.1001376-Stevens1" ref-type="bibr">[23]</xref>
</td><td align="left" rowspan="1" colspan="1">285</td><td align="left" rowspan="1" colspan="1">565</td><td align="left" rowspan="1" colspan="1">50.44</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.9 (0.6 to 1.5)</td><td align="left" rowspan="1" colspan="1">0.773</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">Hospital population</td></tr><tr><td align="left" rowspan="1" colspan="1">Mahmud et al, 2003 <xref rid="pmed.1001376-Mahmud1" ref-type="bibr">[42]</xref>
</td><td align="left" rowspan="1" colspan="1">2678</td><td align="left" rowspan="1" colspan="1">4451</td><td align="left" rowspan="1" colspan="1">60.17</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.9 (0.8 to 1.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.0 (0.8 to 1.2)</td><td align="left" rowspan="1" colspan="1">0.39, 0.958</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">Odds of NOT receiving treatment&#x02014;individual p-values reported</td></tr><tr><td align="left" rowspan="1" colspan="1">Mahmud et al, 2003 <xref rid="pmed.1001376-Mahmud1" ref-type="bibr">[42]</xref>
</td><td align="left" rowspan="1" colspan="1">694</td><td align="left" rowspan="1" colspan="1">1002</td><td align="left" rowspan="1" colspan="1">69.26</td><td align="left" rowspan="1" colspan="1">SCLC</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.0 (0.6 to 1.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.8 (0.5 to 1.3)</td><td align="left" rowspan="1" colspan="1">0.888, 0.358</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y(S)</td><td align="left" rowspan="1" colspan="1">Odds of NOT receiving treatment&#x02014;individual p-values reported</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt128"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.</p></fn><fn id="nt129"><label/><p>CI, confidence interval; NR, not reported; OR, odds ratio; SEP, socioeconomic position; UHCS, universal health care system.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pmed-1001376-t012" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t012</object-id><label>Table 12</label><caption><title>Likelihood of receipt of any type of unspecified treatment by SEP group (non-universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t012-12" xlink:href="pmed.1001376.t012"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Treatment</td><td align="left" rowspan="1" colspan="1">Cohort No./No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">p-Value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-Analysis</td><td align="left" rowspan="1" colspan="1">Further Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ou et al, 2008 <xref rid="pmed.1001376-Ou1" ref-type="bibr">[70]</xref>
</td><td align="left" rowspan="1" colspan="1">18216</td><td align="left" rowspan="1" colspan="1">19700</td><td align="left" rowspan="1" colspan="1">92.47</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1">94.7</td><td align="left" rowspan="1" colspan="1">94.1</td><td align="left" rowspan="1" colspan="1">92.2</td><td align="left" rowspan="1" colspan="1">91.9</td><td align="left" rowspan="1" colspan="1">87.2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Stage I. Univariable analysis</td></tr><tr><td align="left" rowspan="1" colspan="1">Smith et al, 1995 <xref rid="pmed.1001376-Smith1" ref-type="bibr">[66]</xref>
</td><td align="left" rowspan="1" colspan="1">1697</td><td align="left" rowspan="1" colspan="1">2396</td><td align="left" rowspan="1" colspan="1">70.83</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00 (0.91 to 1.11)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.001</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Distant stage</td></tr><tr><td align="left" rowspan="1" colspan="1">Smith et al, 1995 <xref rid="pmed.1001376-Smith1" ref-type="bibr">[66]</xref>
</td><td align="left" rowspan="1" colspan="1">2343</td><td align="left" rowspan="1" colspan="1">2813</td><td align="left" rowspan="1" colspan="1">83.29</td><td align="left" rowspan="1" colspan="1">NSCLC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00 (0.88 to 1.13)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.001</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Local stage</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt130"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position; Q5, low socioeconomic position.</p></fn><fn id="nt131"><label/><p>CI, confidence interval; non-UHCS, non-universal health care system; NR, not reported; OR, odds ratio; pop, population; SE, standard error; SEP, socioeconomic position.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pmed-1001376-t013" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001376.t013</object-id><label>Table 13</label><caption><title>Likelihood of receipt of any type of unspecified curative treatment by SEP group (universal health care systems).</title></caption><alternatives><graphic id="pmed-1001376-t013-13" xlink:href="pmed.1001376.t013"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study</td><td align="left" rowspan="1" colspan="1">No. Receiving Treatment</td><td align="left" rowspan="1" colspan="1">Cohort No. / No. Eligible</td><td align="left" rowspan="1" colspan="1">Rate/ Eligible Rate</td><td align="left" rowspan="1" colspan="1">Histology</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q1 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q2 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q3 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q4 (95% CI)</td><td align="left" rowspan="1" colspan="1">OR/Rate in Q5 (95% CI)</td><td align="left" rowspan="1" colspan="1">p-Value</td><td align="left" rowspan="1" colspan="1">Quality Score</td><td align="left" rowspan="1" colspan="1">Meta-Analysis</td><td align="left" rowspan="1" colspan="1">Further Information</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Erridge et al, 2009 <xref rid="pmed.1001376-Erridge1" ref-type="bibr">[18]</xref>
</td><td align="left" rowspan="1" colspan="1">548</td><td align="left" rowspan="1" colspan="1">3833</td><td align="left" rowspan="1" colspan="1">14.30</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.1(0.9 to 1.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y (S)</td><td align="left" rowspan="1" colspan="1">Scottish pop &#x02013; subset of Gregor et al (2001) pop</td></tr><tr><td align="left" rowspan="1" colspan="1">Erridge et al, 2009 <xref rid="pmed.1001376-Erridge1" ref-type="bibr">[18]</xref>
</td><td align="left" rowspan="1" colspan="1">546</td><td align="left" rowspan="1" colspan="1">2073</td><td align="left" rowspan="1" colspan="1">26.34</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.4(1.1 to 1.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Canadian pop</td></tr><tr><td align="left" rowspan="1" colspan="1">Gregor et al, 2001 <xref rid="pmed.1001376-Gregor1" ref-type="bibr">[38]</xref>
</td><td align="left" rowspan="1" colspan="1">627</td><td align="left" rowspan="1" colspan="1">3855/1423</td><td align="left" rowspan="1" colspan="1">16.26/44.06</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.14 (0.72 to 1.80)</td><td align="left" rowspan="1" colspan="1">1.07 (0.69 to 1.66)</td><td align="left" rowspan="1" colspan="1">0.95 (0.62 to 1.47)</td><td align="left" rowspan="1" colspan="1">0.77 (0.51 to 1.16)</td><td align="left" rowspan="1" colspan="1">0.25</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Eligible &#x0200a;=&#x0200a; early stage</td></tr><tr><td align="left" rowspan="1" colspan="1">Stevens et al, 2008 <xref rid="pmed.1001376-Stevens2" ref-type="bibr">[47]</xref>
</td><td align="left" rowspan="1" colspan="1">109</td><td align="left" rowspan="1" colspan="1">565</td><td align="left" rowspan="1" colspan="1">19.29</td><td align="left" rowspan="1" colspan="1">any</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">3.1 (1.0 to 9.7)</td><td align="left" rowspan="1" colspan="1">1.4 (0.4 to 4.4)</td><td align="left" rowspan="1" colspan="1">1.1 (0.4 to 0.3)</td><td align="left" rowspan="1" colspan="1">0.6 (0.2 to 1.8)</td><td align="left" rowspan="1" colspan="1">0.05, 0.60, 0.86, 0.40</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Hospital pop - subset of Stevens et al (2007) pop, individual p-values reported</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt132"><label/><p>Some studies reported SEP quintiles but others reported SEP in 2, 3, or 4 categories or as a continuous variable. Details of the number of SEP groups per study are given in <xref ref-type="table" rid="pmed-1001376-t001">Tables 1</xref>&#x02013;<xref ref-type="table" rid="pmed-1001376-t004">4</xref> in the column entitled &#x0201c;No. of SEP groups.&#x0201d; Quality scores range from 1 (lowest quality) to 6 (highest quality). Meta-analysis: Y, included in final meta-analysis; Y(S), included in sensitivity meta-analysis; N, not included in meta-analysis. Q1, high socioeconomic position, Q5, low socioeconomic position.</p></fn><fn id="nt133"><label/><p>CI, confidence interval; NR, not reported; OR, odds ratio; pop, population; SEP, socioeconomic position; UHCS, universal health care system.</p></fn></table-wrap-foot></table-wrap><p>When the surgery, chemotherapy, and radiotherapy papers included in the separate treatment meta-analyses in this systematic review were analysed together to produce an overall summary effect meta-analysis OR, a similar result was seen, with low SEP associated with a lower likelihood of receiving any type of treatment. This was found when including only studies with non-overlapping populations (OR&#x0200a;=&#x0200a;0.79 [95% CI 0.73 to 0.86], p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;77%) (<xref ref-type="supplementary-material" rid="pmed.1001376.s006">Figure S6</xref>) and when including all eligible studies (OR&#x0200a;=&#x0200a;0.80 [95% CI 0.75 to 0.86], p&#x0003c;0.001, I<sup>2</sup>&#x0200a;=&#x0200a;82%) (<xref ref-type="supplementary-material" rid="pmed.1001376.s007">Figure S7</xref>).</p></sec></sec><sec id="s4"><title>Discussion</title><sec id="s4a"><title>Principal Findings</title><p>To our knowledge, this is the first systematic review and meta-analysis examining socioeconomic inequalities in receipt of lung cancer treatment. It shows an association between low SEP and reduced likelihood of receipt of any type of treatment, surgery, and chemotherapy. The results were generally consistent across different health care systems.</p></sec><sec id="s4b"><title>Interpretation of Results</title><p>Surgery is suitable only for patients with early-stage NSCLC, and it has been suggested that patients with cancer in a lower SEP are more likely to present later and with later-stage disease <xref rid="pmed.1001376-Dalton1" ref-type="bibr">[20]</xref>. This may help explain why socioeconomic inequalities in receipt of surgery are observed in some studies. However, presentation with later-stage cancer in lower SEP patients has not been consistently observed <xref rid="pmed.1001376-Berglund1" ref-type="bibr">[19]</xref>. In this review, when receipt of treatment was examined in studies of early-stage patients only (from non-UHCS studies), low SEP remained associated with reduced likelihood of surgery. Thus, the association between SEP and receipt of surgery appears to be independent of stage. Similar results were seen for NSCLC studies in both health care systems.</p><p>Receipt of treatment may also be influenced by clinical suitability for treatment, and socioeconomic differences in the number of co-morbidities present may explain socioeconomic inequalities in treatment. In the three UHCS studies that took co-morbidity into account, SEP was not associated with receipt of surgery <xref rid="pmed.1001376-Rich1" ref-type="bibr">[21]</xref>,<xref rid="pmed.1001376-Berglund2" ref-type="bibr">[22]</xref> or of any treatment <xref rid="pmed.1001376-Stevens1" ref-type="bibr">[23]</xref> when the trend across SEP groups was examined, suggesting that co-morbidity may be a potential mediator of socioeconomic inequalities in treatment in UHCSs. However, most of the non-UHCS studies did include co-morbidity as a confounder, and socioeconomic inequalities in treatment were still observed, suggesting that there may be differences between health care systems here.</p></sec><sec id="s4c"><title>Strengths and Weaknesses of the Review and of the Available Evidence</title><p>This is one of the first equity reviews published <xref rid="pmed.1001376-Welch1" ref-type="bibr">[24]</xref>,<xref rid="pmed.1001376-Thomas1" ref-type="bibr">[25]</xref>, the first systematic review of the literature on intervention-generated inequalities in lung cancer treatment to our knowledge, and the first cancer equity review to include a meta-analysis. Extensive searches were carried out to identify studies. However, it is possible that not all relevant studies were obtained.</p><p>The included studies reported observational data only. The suitability of meta-analysis for observational studies has been questioned, as it may produce precise but spurious results <xref rid="pmed.1001376-Egger1" ref-type="bibr">[26]</xref>. Examining the possible sources of heterogeneity by conducting sensitivity analyses across different sub-groups may be less prone to bias than calculating an overall summary effect <xref rid="pmed.1001376-Egger1" ref-type="bibr">[26]</xref>. Here, although an overall summary effect OR was calculated, heterogeneity was taken into account. Separate analyses by type of treatment were carried out, with further stratification by stage and histology. Universal and non-UHCSs were examined separately and random effects rather than fixed effects meta-analyses were conducted. These precautions did not change the overall pattern of results seen.</p><p>Significant heterogeneity remained in some cases, which could be considered a limitation, although this is not surprising because of the characteristics of the studies included. For studies examining receipt of chemotherapy and radiotherapy it was generally not possible to differentiate between curative and palliative treatment and, if patterns of care differ for these by SEP, this might explain the high degree of heterogeneity seen. However, although there is some suggestion that heterogeneity can be considered high at &#x0003e;50% <xref rid="pmed.1001376-The1" ref-type="bibr">[17]</xref>, when confidence intervals were calculated these were wide, so it was difficult to be confident about the degree of heterogeneity present <xref rid="pmed.1001376-Ioannidis1" ref-type="bibr">[27]</xref>.</p><p>
<xref ref-type="sec" rid="s3">Results</xref> for receipt of radiotherapy differed in the non-UHCS sub-group compared to overall but, as only two studies were included in this sub-group, it is difficult to be sure that different patterns of receipt of radiotherapy by SEP are due to differences in health care system.</p><p>Many of the non-UHCS studies used overlapping population sub-groups from the SEER database. There was also population overlap between some UHCS datasets. We attempted to include only substantially non-overlapping datasets within the final meta-analyses to ensure independence of results. A judgement had to be made as to which was the best-quality and most appropriate paper to include, but sensitivity analyses using different inclusion combinations (<xref ref-type="supplementary-material" rid="pmed.1001376.s008">Figure S8</xref>) did not change the overall findings, nor did including all suitable studies regardless of population overlap (<xref ref-type="supplementary-material" rid="pmed.1001376.s001">Figures S1</xref>, <xref ref-type="supplementary-material" rid="pmed.1001376.s003">S3</xref>, <xref ref-type="supplementary-material" rid="pmed.1001376.s004">S4</xref>, <xref ref-type="supplementary-material" rid="pmed.1001376.s005">S5</xref>, <xref ref-type="supplementary-material" rid="pmed.1001376.s007">S7</xref>).</p><p>Included papers contained data for patients diagnosed between 1978 and 2008. As treatment guidance has changed over time, older studies may be less applicable to current clinical practice. However, the majority of included studies were published within the last five years, and sensitivity analyses excluding studies published prior to 2000 did not change the overall findings.</p><p>Various measures of SEP were used, and these were categorised differently&#x02014;an acknowledged problem in equity reviews <xref rid="pmed.1001376-Ogilvie1" ref-type="bibr">[28]</xref>. All but one study measured SEP at the area level. This is a further limitation, as area-based measures of SEP are unlikely to be accurate markers of individual-level circumstances and access to resources <xref rid="pmed.1001376-Adams1" ref-type="bibr">[29]</xref>. Area-based measures of SEP can be calculated using address, making them easy to add to disease registers, such as those used in many of the studies synthesised here. However, the reliance on area-based markers of SEP may underestimate the strength of the true association between SEP and receipt of treatment.</p><p>Not all studies reported details of stage and histology&#x02014;both of which influence treatment type&#x02014;and very few UHCS studies took co-morbidity into account. Thus, the ORs used in the meta-analyses were not consistently adjusted for the same covariates. However, we attempted to take these factors into account in the quality scores and by conducting subgroup sensitivity analyses. Examining only high-quality studies did not alter our findings nor did sensitivity analyses, although consequent reduction in numbers did result in loss of significance in some analyses, potentially due to lack of power to detect differences.</p><p>In order to conduct meta-analysis it is necessary to compare the odds of treatment in the lowest-SEP group with the odds in the highest, which simplifies what may be a complex relationship across SEP groups. However, studies that reported a change in odds ratios across the SEP categories, and thus explored trends in receipt of treatment, generally supported the overall findings of the review.</p><p>A number of existing tools suitable for assessing cohort study quality were considered <xref rid="pmed.1001376-SIGN1" ref-type="bibr">[15]</xref>,<xref rid="pmed.1001376-Vandenbroucke1" ref-type="bibr">[16]</xref>. However, none of these tools was entirely appropriate for the type of studies included and, as has been done in previous reviews <xref rid="pmed.1001376-Slatore1" ref-type="bibr">[13]</xref>,<xref rid="pmed.1001376-Olsson1" ref-type="bibr">[30]</xref>, we devised a unique tool, adapting and utilising aspects of other available tools. This approach has the benefit of producing a quality tool that is highly specific for the type of studies examined.</p><p>As with any systematic review, we are unable to exclude the possibility of publication bias. Studies reporting null findings are less likely to be published or, if they are published, not to report numerical outcomes <xref rid="pmed.1001376-The1" ref-type="bibr">[17]</xref>. A funnel plot to assess potential publication bias did not show obvious bias (<xref ref-type="supplementary-material" rid="pmed.1001376.s009">Figure S9</xref>). However, a number of papers recovered in the search included SEP in the description of the study population but did not report receipt of treatment by SEP <xref rid="pmed.1001376-Grose1" ref-type="bibr">[31]</xref>&#x02013;<xref rid="pmed.1001376-Riaz1" ref-type="bibr">[34]</xref>. Study authors were contacted and asked to provide further information, but only one supplied the requested data <xref rid="pmed.1001376-Riaz1" ref-type="bibr">[34]</xref>. It is likely that SEP was not significantly associated with receipt of treatment in the other studies, but this was not always clearly reported. However, publication bias is thought to be less important than other sources of bias, such as confounding, in meta-analyses of observational studies <xref rid="pmed.1001376-Egger1" ref-type="bibr">[26]</xref>.</p></sec><sec id="s4d"><title>Implications for Policy and Practice</title><p>Socioeconomic inequalities in receipt of treatment may exacerbate socioeconomic inequalities in incidence of lung cancer, which is strongly associated with higher smoking rates in more deprived populations, so may further contribute to the poorer outcomes in lower SEP groups.</p><p>Socioeconomic inequalities in treatment may be due to differences in access to care. Within a non-UHCS it might be expected that socioeconomic differences in receipt of treatment would be observed due to income-related differences in health insurance status. Patients with lung cancer in the USA who do not have insurance have been shown to have more limited access to care <xref rid="pmed.1001376-Slatore1" ref-type="bibr">[13]</xref>. However, as socioeconomic inequalities in receipt of lung cancer treatment were also observed in UHCSs that do not depend on ability to pay and in non-UHCS studies where insurance type was taken into account, this would suggest that other system factors may be contributing to this inequality. The extent to which receipt of treatment is influenced by factors such as patient choice is not known.</p><p>Variability at the patient, tumour, system, and individual clinician levels needs to be investigated before clear recommendations for changes to policy and practice can be made.</p></sec><sec id="s4e"><title>Future Research</title><p>This review has demonstrated a clear association between lower SEP and reduced likelihood of receiving surgery, chemotherapy, and any type of unspecified treatment for lung cancer. The reasons for these inequalities need to be more thoroughly investigated. Better-quality UHCS studies, including statistical control for co-morbidity and stratification by stage and histology&#x02014;so that only those patients eligible for a particular treatment are included in the population-denominator&#x02014;are required. It would also be useful to be able to distinguish between curative and palliative intent of treatment. In non-UHCS, studies in younger populations, examining a range of insurance providers, are required.</p><p>Further investigation into the system and patient factors that might contribute to socioeconomic inequalities in receipt of lung cancer care is necessary, to help develop interventions that ensure equitable receipt of appropriate treatment. This should include a quantitative exploration of inequalities at each stage of the care pathway as well as qualitative work exploring reasons for inequality. Inequalities in receipt of treatment may contribute to inequalities in cancer survival and so cohort survival analyses are warranted in order to investigate intervention-generated inequalities in lung cancer outcomes.</p></sec></sec><sec sec-type="supplementary-material" id="s6"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pmed.1001376.s001"><label>Figure S1</label><caption><p>
<bold>Meta-analysis of odds of receipt of surgery in low versus high SEP (overlapping populations).</bold> CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s002"><label>Figure S2</label><caption><p>
<bold>Meta-analysis of odds of receipt of surgery for NSCLC in low versus high SEP (non-overlapping populations).</bold> CI, confidence interval; OR, odds ratio; SE, standard error; SEP, socioeconomic position.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s003"><label>Figure S3</label><caption><p>
<bold>Meta-analysis of odds of receipt of chemotherapy in low versus high SEP (overlapping populations).</bold> CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s004"><label>Figure S4</label><caption><p>
<bold>Meta-analysis of odds of receipt of radiotherapy in low versus high SEP (overlapping populations).</bold> CI&#x0200a;=&#x0200a;confidence interval, non-UHCS&#x0200a;=&#x0200a;non-universal health care system, OR&#x0200a;=&#x0200a;odds ratio, SE&#x0200a;=&#x0200a;standard error, SEP&#x0200a;=&#x0200a;socioeconomic position UHCS&#x0200a;=&#x0200a;universal health care system.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s004.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s005"><label>Figure S5</label><caption><p>
<bold>Sensitivity meta-analysis of odds of receipt unspecified treatment in low versus high SEP (overlapping populations).</bold> CI, confidence interval; OR, odds ratio; SE, standard error; SEP, socioeconomic position.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s005.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s006"><label>Figure S6</label><caption><p>
<bold>Meta-analysis of odds of receipt of any type of treatment in low versus high SEP.</bold> CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s006.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s007"><label>Figure S7</label><caption><p>
<bold>Meta-analysis of odds of receipt of any type of treatment in low versus high SEP (overlapping populations).</bold> CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s007.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s008"><label>Figure S8</label><caption><p>
<bold>Meta-analysis of odds of receipt of surgery in low versus high SEP (partially-overlapping populations).</bold> CI, confidence interval; non-UHCS, non-universal health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s008.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s009"><label>Figure S9</label><caption><p>
<bold>Funnel plot to assess publication bias.</bold> CI, confidence interval; non-UHCS, non-universal health care system; NSCLC, non-small cell lung cancer; UHCS, universal health care system.</p><p>(TIF)</p></caption><media xlink:href="pmed.1001376.s009.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s010"><label>Table S1</label><caption><p>
<bold>Full search strategies (MEDLINE and EMBASE).</bold>
</p><p>(DOC)</p></caption><media xlink:href="pmed.1001376.s010.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s011"><label>Text S1</label><caption><p>
<bold>PRISMA checklist.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pmed.1001376.s011.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s012"><label>Text S2</label><caption><p>
<bold>Protocol.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pmed.1001376.s012.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001376.s013"><label>Text S3</label><caption><p>
<bold>Quality score checklist.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pmed.1001376.s013.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pmed.1001376-Cancer1"><label>1</label><mixed-citation publication-type="other">Cancer Research UK Cancer incidence: UK statistics. Available: <ext-link ext-link-type="uri" xlink:href="http://info.cancerresearchuk.org/cancerstats/incidence/">http://info.cancerresearchuk.org/cancerstats/incidence/</ext-link>. Accessed 09 January 2013.</mixed-citation></ref><ref id="pmed.1001376-Howlader1"><label>2</label><mixed-citation publication-type="other">Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, <etal>et al</etal>
<comment>.. (eds). SEER Cancer Statistics Review, 1975&#x02013;2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. Based on November 2011 SEER data submission, posted to the SEER web site, April 2012. Available: <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/csr/1975_2009_pops09/">http://seer.cancer.gov/csr/1975_2009_pops09/</ext-link>. Accessed 09 January 2012.</comment>
</mixed-citation></ref><ref id="pmed.1001376-Cancer2"><label>3</label><mixed-citation publication-type="other">Cancer Research UK Common cancers - UK mortality statistics. Available: <ext-link ext-link-type="uri" xlink:href="http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/">http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/</ext-link>. Accessed 09 January 2013.</mixed-citation></ref><ref id="pmed.1001376-Coleman1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Coleman</surname><given-names>MP</given-names></name>, <name><surname>Forman</surname><given-names>D</given-names></name>, <name><surname>Bryant</surname><given-names>H</given-names></name>, <name><surname>Butler</surname><given-names>J</given-names></name>, <name><surname>Rachet</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995&#x02013;2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data</article-title>. <source>Lancet</source>
<volume>377</volume>: <fpage>127</fpage>&#x02013;<lpage>138</lpage>.<pub-id pub-id-type="pmid">21183212</pub-id></mixed-citation></ref><ref id="pmed.1001376-Verdecchia1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Verdecchia</surname><given-names>A</given-names></name>, <name><surname>Francisci</surname><given-names>S</given-names></name>, <name><surname>Brenner</surname><given-names>H</given-names></name>, <name><surname>Gatta</surname><given-names>G</given-names></name>, <name><surname>Micheli</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Recent cancer survival in Europe: a 2000&#x02013;02 period analysis of EUROCARE-4 data</article-title>. <source>Lancet Oncol</source>
<volume>8</volume>: <fpage>784</fpage>&#x02013;<lpage>796</lpage>.<pub-id pub-id-type="pmid">17714993</pub-id></mixed-citation></ref><ref id="pmed.1001376-NICE1"><label>6</label><mixed-citation publication-type="other">NICE (2005) Clinical Guideline 24. Lung Cancer: the diagnosis and treatment of lung cancer. London: NICE.</mixed-citation></ref><ref id="pmed.1001376-Rachet1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Rachet</surname><given-names>B</given-names></name>, <name><surname>Ellis</surname><given-names>L</given-names></name>, <name><surname>Maringe</surname><given-names>C</given-names></name>, <name><surname>Chu</surname><given-names>T</given-names></name>, <name><surname>Nur</surname><given-names>U</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Socioeconomic inequalities in cancer survival in England after the NHS cancer plan</article-title>. <source>Br J Cancer</source>
<volume>103</volume>: <fpage>446</fpage>&#x02013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">20588275</pub-id></mixed-citation></ref><ref id="pmed.1001376-Aarts1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Aarts</surname><given-names>MJ</given-names></name>, <name><surname>Lemmens</surname><given-names>VEPP</given-names></name>, <name><surname>Louwman</surname><given-names>MWJ</given-names></name>, <name><surname>Kunst</surname><given-names>AE</given-names></name>, <name><surname>Coebergh</surname><given-names>JWW</given-names></name> (<year>2010</year>) <article-title>Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome</article-title>. <source>Eur J Cancer</source>
<volume>46</volume>: <fpage>2681</fpage>&#x02013;<lpage>2695</lpage>.<pub-id pub-id-type="pmid">20570136</pub-id></mixed-citation></ref><ref id="pmed.1001376-Woods1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Woods</surname><given-names>LM</given-names></name>, <name><surname>Rachet</surname><given-names>B</given-names></name>, <name><surname>Coleman</surname><given-names>MP</given-names></name> (<year>2006</year>) <article-title>Origins of socio-economic inequalities in cancer survival: a review</article-title>. <source>Ann Oncol</source>
<volume>17</volume>: <fpage>5</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">16143594</pub-id></mixed-citation></ref><ref id="pmed.1001376-White1"><label>10</label><mixed-citation publication-type="other">White M, Adams J, Heywood P (2009) How and why do interventions that increase health overall widen inequalities within populations? In: Babones S, editor. Health, inequality and society. Bristol: Policy Press.</mixed-citation></ref><ref id="pmed.1001376-Sidorchuk1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Sidorchuk</surname><given-names>A</given-names></name>, <name><surname>Agardh</surname><given-names>E</given-names></name>, <name><surname>Aremu</surname><given-names>O</given-names></name>, <name><surname>Hallqvist</surname><given-names>J</given-names></name>, <name><surname>Allebeck</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Socioeconomic differences in lung cancer incidence: a systematic review and meta-analysis</article-title>. <source>Cancer Causes Control</source>
<volume>20</volume>: <fpage>459</fpage>&#x02013;<lpage>471</lpage>.<pub-id pub-id-type="pmid">19184626</pub-id></mixed-citation></ref><ref id="pmed.1001376-Moher1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Moher</surname><given-names>D</given-names></name>, <name><surname>Liberati</surname><given-names>A</given-names></name>, <name><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name> (<year>2009</year>) <collab>The PRISMA Group</collab> (<year>2009</year>) <article-title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement</article-title>. <source>PLoS Med</source>
<volume>6</volume>
<issue>7</issue>: <fpage>e1000097</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000097">10.1371/journal.pmed.1000097</ext-link></comment>.<pub-id pub-id-type="pmid">19621072</pub-id></mixed-citation></ref><ref id="pmed.1001376-Slatore1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Slatore</surname><given-names>CG</given-names></name>, <name><surname>Au</surname><given-names>DH</given-names></name>, <name><surname>Gould</surname><given-names>MK</given-names></name> (<year>2010</year>) <collab>on behalf of the American Thoracic Society Disparities in Healthcare G</collab> (<year>2010</year>) <article-title>An Official American Thoracic Society Systematic Review: Insurance Status and Disparities in Lung Cancer Practices and Outcomes</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>182</volume>: <fpage>1195</fpage>&#x02013;<lpage>1205</lpage>.<pub-id pub-id-type="pmid">21041563</pub-id></mixed-citation></ref><ref id="pmed.1001376-Donaldson1"><label>14</label><mixed-citation publication-type="other">Donaldson C, Gerard K (2005) Health care financing reforms: moving into the new millenium. Economics of Health Care Financing: The Visible Hand. Basingstoke: Palgrave Macmillan.</mixed-citation></ref><ref id="pmed.1001376-SIGN1"><label>15</label><mixed-citation publication-type="other">SIGN (2011) SIGN 50: A Guideline Developer's Handbook. Methodology Checklist 3: Cohort studies. Edinburgh: SIGN.</mixed-citation></ref><ref id="pmed.1001376-Vandenbroucke1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Vandenbroucke</surname><given-names>JP</given-names></name>, <name><surname>von Elm</surname><given-names>E</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <name><surname>G&#x000f8;tzsche</surname><given-names>PC</given-names></name>, <name><surname>Mulrow</surname><given-names>CD</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration</article-title>. <source>PLoS Med</source>
<volume>4</volume>
<issue>10</issue>: <fpage>e297</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0040297">10.1371/journal.pmed.0040297</ext-link></comment>.<pub-id pub-id-type="pmid">17941715</pub-id></mixed-citation></ref><ref id="pmed.1001376-The1"><label>17</label><mixed-citation publication-type="other">The Cochrane Collaboration (2008) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. Higgins J, Green S, editors.</mixed-citation></ref><ref id="pmed.1001376-Erridge1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Erridge</surname><given-names>SC</given-names></name>, <name><surname>Murray</surname><given-names>B</given-names></name>, <name><surname>Williams</surname><given-names>L</given-names></name>, <name><surname>Brewster</surname><given-names>D</given-names></name>, <name><surname>Black</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Improved survival from lung cancer in British Columbia compared to Scotland-Are different treatment rates the whole story?</article-title>
<source>Lung Cancer</source>
<volume>64</volume>: <fpage>358</fpage>&#x02013;<lpage>366</lpage>.<pub-id pub-id-type="pmid">19036470</pub-id></mixed-citation></ref><ref id="pmed.1001376-Berglund1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Berglund</surname><given-names>A</given-names></name>, <name><surname>Holmberg</surname><given-names>L</given-names></name>, <name><surname>Tishelman</surname><given-names>C</given-names></name>, <name><surname>Wagenius</surname><given-names>G</given-names></name>, <name><surname>Eaker</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Social inequalities in non-small cell lung cancer management and survival: a population-based study in central Sweden</article-title>. <source>Thorax</source>
<volume>65</volume>: <fpage>327</fpage>&#x02013;<lpage>333</lpage>.<pub-id pub-id-type="pmid">20388758</pub-id></mixed-citation></ref><ref id="pmed.1001376-Dalton1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Dalton</surname><given-names>SO</given-names></name>, <name><surname>Frederiksen</surname><given-names>BL</given-names></name>, <name><surname>Jacobsen</surname><given-names>E</given-names></name>, <name><surname>Steding-Jessen</surname><given-names>M</given-names></name>, <name><surname>Osterlind</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Socioeconomic position, stage of lung cancer and time between referral and diagnosis in Denmark, 2001&#x02013;2008</article-title>. <source>Br J Cancer</source>
<volume>105</volume>: <fpage>1042</fpage>&#x02013;<lpage>1048</lpage>.<pub-id pub-id-type="pmid">21897390</pub-id></mixed-citation></ref><ref id="pmed.1001376-Rich1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Rich</surname><given-names>AL</given-names></name>, <name><surname>Tata</surname><given-names>LJ</given-names></name>, <name><surname>Free</surname><given-names>CM</given-names></name>, <name><surname>Stanley</surname><given-names>RA</given-names></name>, <name><surname>Peake</surname><given-names>MD</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service</article-title>. <source>Thorax</source>
<volume>66</volume>: <fpage>1078</fpage>&#x02013;<lpage>1084</lpage>.<pub-id pub-id-type="pmid">21785158</pub-id></mixed-citation></ref><ref id="pmed.1001376-Berglund2"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Berglund</surname><given-names>A</given-names></name>, <name><surname>Lambe</surname><given-names>M</given-names></name>, <name><surname>L&#x000fc;chtenborg</surname><given-names>M</given-names></name>, <name><surname>Linklater</surname><given-names>K</given-names></name>, <name><surname>Peake</surname><given-names>MD</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Social differences in lung cancer management and survival in South East England: a cohort study</article-title>. <source>BMJ Open</source>
<volume>2</volume>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmjopen-2012-001048">10.1136/bmjopen-2012-001048</ext-link></comment>.</mixed-citation></ref><ref id="pmed.1001376-Stevens1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Stevens</surname><given-names>W</given-names></name>, <name><surname>Stevens</surname><given-names>G</given-names></name>, <name><surname>Kolbe</surname><given-names>J</given-names></name>, <name><surname>Cox</surname><given-names>B</given-names></name> (<year>2007</year>) <article-title>Lung cancer in New Zealand: Patterns of secondary care and implications for survival</article-title>. <source>J Thorac Oncol</source>
<volume>2</volume>: <fpage>481</fpage>&#x02013;<lpage>493</lpage>.<pub-id pub-id-type="pmid">17545842</pub-id></mixed-citation></ref><ref id="pmed.1001376-Welch1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Welch</surname><given-names>V</given-names></name>, <name><surname>Petticrew</surname><given-names>M</given-names></name>, <name><surname>Ueffing</surname><given-names>E</given-names></name>, <name><surname>Benkhalti Jandu</surname><given-names>M</given-names></name>, <name><surname>Brand</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Does Consideration and Assessment of Effects on Health Equity Affect the Conclusions of Systematic Reviews? A Methodology Study</article-title>. <source>PLoS ONE</source>
<volume>7</volume>
<issue>3</issue>: <fpage>e31360</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0031360">10.1371/journal.pone.0031360</ext-link></comment>.<pub-id pub-id-type="pmid">22427804</pub-id></mixed-citation></ref><ref id="pmed.1001376-Thomas1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Thomas</surname><given-names>S</given-names></name>, <name><surname>Fayter</surname><given-names>D</given-names></name>, <name><surname>Misso</surname><given-names>K</given-names></name>, <name><surname>Ogilvie</surname><given-names>D</given-names></name>, <name><surname>Petticrew</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Population tobacco control interventions and their effects on social inequalities in smoking: systematic review</article-title>. <source>Tob Control</source>
<volume>17</volume>: <fpage>230</fpage>&#x02013;<lpage>237</lpage>.<pub-id pub-id-type="pmid">18426867</pub-id></mixed-citation></ref><ref id="pmed.1001376-Egger1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>Schneider</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>GD</given-names></name> (<year>1998</year>) <article-title>Meta-analysis Spurious precision? Meta-analysis of observational studies</article-title>. <source>BMJ</source>
<volume>316</volume>: <fpage>140</fpage>&#x02013;<lpage>144</lpage>.<pub-id pub-id-type="pmid">9462324</pub-id></mixed-citation></ref><ref id="pmed.1001376-Ioannidis1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Ioannidis</surname><given-names>J</given-names></name>, <name><surname>Patsopoulos</surname><given-names>N</given-names></name>, <name><surname>Evangelou</surname><given-names>E</given-names></name> (<year>2007</year>) <article-title>Uncertainty in heterogeneity estimates in meta-analyses</article-title>. <source>BMJ</source>
<volume>335</volume>: <fpage>914</fpage>&#x02013;<lpage>916</lpage>.<pub-id pub-id-type="pmid">17974687</pub-id></mixed-citation></ref><ref id="pmed.1001376-Ogilvie1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Ogilvie</surname><given-names>D</given-names></name>, <name><surname>Fayter</surname><given-names>D</given-names></name>, <name><surname>Petticrew</surname><given-names>M</given-names></name>, <name><surname>Sowden</surname><given-names>A</given-names></name>, <name><surname>Thomas</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The harvest plot: A method for synthesising evidence about the differential effects of interventions</article-title>. <source>BMC Med Res Methodol</source>
<volume>8</volume>: <fpage>8</fpage>.<pub-id pub-id-type="pmid">18298827</pub-id></mixed-citation></ref><ref id="pmed.1001376-Adams1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Adams</surname><given-names>J</given-names></name>, <name><surname>Ryan</surname><given-names>V</given-names></name>, <name><surname>White</surname><given-names>M</given-names></name> (<year>2005</year>) <article-title>How accurate are Townsend Deprivation Scores as predictors of self-reported health? A comparison with individual level data</article-title>. <source>J Public Health</source>
<volume>27</volume>: <fpage>101</fpage>&#x02013;<lpage>106</lpage>.</mixed-citation></ref><ref id="pmed.1001376-Olsson1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Olsson</surname><given-names>JK</given-names></name>, <name><surname>Schultz</surname><given-names>EM</given-names></name>, <name><surname>Gould</surname><given-names>MK</given-names></name> (<year>2009</year>) <article-title>Timeliness of care in patients with lung cancer: a systematic review</article-title>. <source>Thorax</source>
<volume>64</volume>: <fpage>749</fpage>&#x02013;<lpage>756</lpage>.<pub-id pub-id-type="pmid">19717709</pub-id></mixed-citation></ref><ref id="pmed.1001376-Grose1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Grose</surname><given-names>D</given-names></name>, <name><surname>Devereux</surname><given-names>G</given-names></name>, <name><surname>Brown</surname><given-names>L</given-names></name>, <name><surname>Jones</surname><given-names>R</given-names></name>, <name><surname>Sharma</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Variation in comorbidity and clinical management in patients newly diagnosed with lung cancer in four Scottish centers</article-title>. <source>J Thorac Oncol</source>
<volume>6</volume>: <fpage>500</fpage>&#x02013;<lpage>509</lpage>.<pub-id pub-id-type="pmid">21258251</pub-id></mixed-citation></ref><ref id="pmed.1001376-Hall1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Hall</surname><given-names>SE</given-names></name>, <name><surname>Bulsara</surname><given-names>CE</given-names></name>, <name><surname>Bulsara</surname><given-names>MK</given-names></name>, <name><surname>Leahy</surname><given-names>TG</given-names></name>, <name><surname>Culbong</surname><given-names>MR</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Treatment patterns for cancer in Western Australia: Does being indigenous make a difference?</article-title>
<source>Med J Aust</source>
<volume>181</volume>: <fpage>191</fpage>&#x02013;<lpage>194</lpage>.<pub-id pub-id-type="pmid">15310252</pub-id></mixed-citation></ref><ref id="pmed.1001376-McCann1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>McCann</surname><given-names>J</given-names></name>, <name><surname>Artinian</surname><given-names>V</given-names></name>, <name><surname>Duhaime</surname><given-names>L</given-names></name>, <name><surname>Lewis</surname><given-names>JW</given-names></name>, <name><surname>Kvale</surname><given-names>PA</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Evaluation of the Causes for Racial Disparity in Surgical Treatment of Early Stage Lung Cancer</article-title>. <source>Chest</source>
<volume>128</volume>: <fpage>3440</fpage>&#x02013;<lpage>3446</lpage>.<pub-id pub-id-type="pmid">16304297</pub-id></mixed-citation></ref><ref id="pmed.1001376-Riaz1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Riaz</surname><given-names>SP</given-names></name>, <name><surname>L&#x000fc;chtenborg</surname><given-names>M</given-names></name>, <name><surname>Jack</surname><given-names>RH</given-names></name>, <name><surname>Coupland</surname><given-names>VH</given-names></name>, <name><surname>Linklater</surname><given-names>KM</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Variation in surgical resection for lung cancer in relation to survival: Population-based study in England 2004&#x02013;2006</article-title>. <source>Eur J Cancer</source>
<volume>48</volume>: <fpage>54</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">21871792</pub-id></mixed-citation></ref><ref id="pmed.1001376-Campbell1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Campbell</surname><given-names>NC</given-names></name>, <name><surname>Elliott</surname><given-names>AM</given-names></name>, <name><surname>Sharp</surname><given-names>L</given-names></name>, <name><surname>Ritchie</surname><given-names>LD</given-names></name>, <name><surname>Cassidy</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Impact of deprivation and rural residence on treatment of colorectal and lung cancer</article-title>. <source>Br J Cancer</source>
<volume>87</volume>: <fpage>585</fpage>&#x02013;<lpage>590</lpage>.<pub-id pub-id-type="pmid">12237766</pub-id></mixed-citation></ref><ref id="pmed.1001376-Crawford1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Crawford</surname><given-names>SM</given-names></name>, <name><surname>Sauerzapf</surname><given-names>V</given-names></name>, <name><surname>Haynes</surname><given-names>R</given-names></name>, <name><surname>Zhao</surname><given-names>H</given-names></name>, <name><surname>Forman</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Social and geographical factors affecting access to treatment of lung cancer</article-title>. <source>Br J Cancer</source>
<volume>101</volume>: <fpage>897</fpage>&#x02013;<lpage>901</lpage>.<pub-id pub-id-type="pmid">19690543</pub-id></mixed-citation></ref><ref id="pmed.1001376-Erridge2"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Erridge</surname><given-names>SC</given-names></name>, <name><surname>Thomson</surname><given-names>CS</given-names></name>, <name><surname>Davidson</surname><given-names>J</given-names></name>, <name><surname>Jones</surname><given-names>RD</given-names></name>, <name><surname>Price</surname><given-names>A</given-names></name> (<year>2002</year>) <article-title>Factors Influencing the Use of Thoracic Radiotherapy in Lung Cancer;an Analysis of the 1995 Scottish Lung Cancer Audit</article-title>. <source>Clin Oncol</source>
<volume>14</volume>: <fpage>219</fpage>&#x02013;<lpage>227</lpage>.</mixed-citation></ref><ref id="pmed.1001376-Gregor1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Gregor</surname><given-names>A</given-names></name>, <name><surname>Thomson</surname><given-names>CS</given-names></name>, <name><surname>Brewster</surname><given-names>DH</given-names></name>, <name><surname>Stroner</surname><given-names>PL</given-names></name>, <name><surname>Davidson</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study</article-title>. <source>Thorax</source>
<volume>56</volume>: <fpage>212</fpage>&#x02013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">11182014</pub-id></mixed-citation></ref><ref id="pmed.1001376-Jack1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Jack</surname><given-names>RH</given-names></name>, <name><surname>Gulliford</surname><given-names>MC</given-names></name>, <name><surname>Ferguson</surname><given-names>J</given-names></name>, <name><surname>Moller</surname><given-names>H</given-names></name> (<year>2003</year>) <article-title>Geographical inequalities in lung cancer management and survival in South East England: evidence of variation in access to oncology services?</article-title>
<source>Br J Cancer</source>
<volume>88</volume>: <fpage>1025</fpage>&#x02013;<lpage>1031</lpage>.<pub-id pub-id-type="pmid">12671698</pub-id></mixed-citation></ref><ref id="pmed.1001376-Jack2"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Jack</surname><given-names>RH</given-names></name>, <name><surname>Gulliford</surname><given-names>MC</given-names></name>, <name><surname>Ferguson</surname><given-names>J</given-names></name>, <name><surname>M&#x000f8;ller</surname><given-names>H</given-names></name> (<year>2006</year>) <article-title>Explaining inequalities in access to treatment in lung cancer</article-title>. <source>J Eval Clin Pract</source>
<volume>12</volume>: <fpage>573</fpage>&#x02013;<lpage>582</lpage>.<pub-id pub-id-type="pmid">16987120</pub-id></mixed-citation></ref><ref id="pmed.1001376-Jones1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Jones</surname><given-names>AP</given-names></name>, <name><surname>Haynes</surname><given-names>R</given-names></name>, <name><surname>Sauerzapf</surname><given-names>V</given-names></name>, <name><surname>Crawford</surname><given-names>SM</given-names></name>, <name><surname>Zhao</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer</article-title>. <source>Eur J Cancer</source>
<volume>44</volume>: <fpage>992</fpage>&#x02013;<lpage>999</lpage>.<pub-id pub-id-type="pmid">18375117</pub-id></mixed-citation></ref><ref id="pmed.1001376-Mahmud1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Mahmud</surname><given-names>SM</given-names></name>, <name><surname>Reilly</surname><given-names>M</given-names></name>, <name><surname>Comber</surname><given-names>H</given-names></name> (<year>2003</year>) <article-title>Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study</article-title>. <source>Lung Cancer</source>
<volume>41</volume>: <fpage>57</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">12826313</pub-id></mixed-citation></ref><ref id="pmed.1001376-McMahon1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>McMahon</surname><given-names>M</given-names></name>, <name><surname>Barbiere</surname><given-names>JM</given-names></name>, <name><surname>Greenberg</surname><given-names>DC</given-names></name>, <name><surname>Wright</surname><given-names>KA</given-names></name>, <name><surname>Lyratzopoulos</surname><given-names>G</given-names></name> (<year>2011</year>) <article-title>Population-based trends in use of surgery for non-small cell lung cancer in a UK region, 1995&#x02013;2006</article-title>. <source>Thorax</source>
<volume>66</volume>: <fpage>453</fpage>&#x02013;<lpage>455</lpage>.<pub-id pub-id-type="pmid">21422037</pub-id></mixed-citation></ref><ref id="pmed.1001376-Pollock1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Pollock</surname><given-names>AM</given-names></name>, <name><surname>Vickers</surname><given-names>N</given-names></name> (<year>1998</year>) <article-title>Deprivation and emergency admissions for cancers of colorectum, lung, and breast in south east England: ecological study</article-title>. <source>BMJ</source>
<volume>317</volume>: <fpage>245</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">9677214</pub-id></mixed-citation></ref><ref id="pmed.1001376-Raine1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Raine</surname><given-names>R</given-names></name>, <name><surname>Wong</surname><given-names>W</given-names></name>, <name><surname>Scholes</surname><given-names>S</given-names></name>, <name><surname>Ashton</surname><given-names>C</given-names></name>, <name><surname>Obichere</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Social variations in access to hospital care for patients with colorectal, breast, and lung cancer between 1999 and 2006: retrospective analysis of hospital episode statistics</article-title>. <source>BMJ</source>
<volume>340</volume>.</mixed-citation></ref><ref id="pmed.1001376-Rich2"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Rich</surname><given-names>AL</given-names></name>, <name><surname>Tata</surname><given-names>LJ</given-names></name>, <name><surname>Stanley</surname><given-names>RA</given-names></name>, <name><surname>Free</surname><given-names>CM</given-names></name>, <name><surname>Peake</surname><given-names>MD</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA)</article-title>. <source>Lung Cancer</source>
<volume>72</volume>: <fpage>16</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">20688413</pub-id></mixed-citation></ref><ref id="pmed.1001376-Stevens2"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Stevens</surname><given-names>W</given-names></name>, <name><surname>Stevens</surname><given-names>G</given-names></name>, <name><surname>Kolbe</surname><given-names>J</given-names></name>, <name><surname>Cox</surname><given-names>B</given-names></name> (<year>2008</year>) <article-title>Ethnic differences in the management of lung cancer in New Zealand</article-title>. <source>J Thorac Oncol</source>
<volume>3</volume>
<issue>3</issue>: <fpage>237</fpage>&#x02013;<lpage>244</lpage>.<pub-id pub-id-type="pmid">18317065</pub-id></mixed-citation></ref><ref id="pmed.1001376-Battersby1"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Battersby</surname><given-names>J</given-names></name>, <name><surname>Flowers</surname><given-names>J</given-names></name>, <name><surname>Harvey</surname><given-names>I</given-names></name> (<year>2004</year>) <article-title>An alternative approach to quantifying and addressing inequity in healthcare provision: access to surgery for lung cancer in the east of England</article-title>. <source>J Epidemiol Community Health</source>
<volume>58</volume>: <fpage>623</fpage>&#x02013;<lpage>625</lpage>.<pub-id pub-id-type="pmid">15194729</pub-id></mixed-citation></ref><ref id="pmed.1001376-Bendzsak1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Bendzsak</surname><given-names>A</given-names></name>, <name><surname>Nenshi</surname><given-names>R</given-names></name>, <name><surname>Darling</surname><given-names>G</given-names></name>, <name><surname>Schultz</surname><given-names>SE</given-names></name>, <name><surname>Gunraj</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Overview of Lung Cancer Surgery in Ontario</article-title>. <source>Ann Thorac Surg</source>
<volume>91</volume>: <fpage>361</fpage>&#x02013;<lpage>366</lpage>.<pub-id pub-id-type="pmid">21256270</pub-id></mixed-citation></ref><ref id="pmed.1001376-Cartman1"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Cartman</surname><given-names>ML</given-names></name>, <name><surname>Hatfield</surname><given-names>AC</given-names></name>, <name><surname>Muers</surname><given-names>MF</given-names></name>, <name><surname>Peake</surname><given-names>MD</given-names></name>, <name><surname>Haward</surname><given-names>RA</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Lung cancer: district active treatment rates affect survival</article-title>. <source>J Epidemiol Community Health</source>
<volume>56</volume>: <fpage>424</fpage>&#x02013;<lpage>429</lpage>.<pub-id pub-id-type="pmid">12011196</pub-id></mixed-citation></ref><ref id="pmed.1001376-Hui1"><label>51</label><mixed-citation publication-type="journal">
<name><surname>Hui</surname><given-names>AC</given-names></name>, <name><surname>Vinod</surname><given-names>SK</given-names></name>, <name><surname>Jalaludin</surname><given-names>BB</given-names></name>, <name><surname>Yuile</surname><given-names>P</given-names></name>, <name><surname>Delaney</surname><given-names>GP</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Socio-economic status and patterns of care in lung cancer</article-title>. <source>Aust N Z J Public Health</source>
<volume>29</volume>: <fpage>372</fpage>&#x02013;<lpage>377</lpage>.<pub-id pub-id-type="pmid">16222936</pub-id></mixed-citation></ref><ref id="pmed.1001376-Madelaine1"><label>52</label><mixed-citation publication-type="journal">
<name><surname>Madelaine</surname><given-names>J</given-names></name>, <name><surname>Guizard</surname><given-names>AV</given-names></name>, <name><surname>Lefevre</surname><given-names>H</given-names></name>, <name><surname>Lecarpentier</surname><given-names>MM</given-names></name>, <name><surname>Launoy</surname><given-names>G</given-names></name> (<year>2002</year>) <article-title>[Diagnosis, treatment, and prognosis of lung cancer in the Manche (France) (1997&#x02013;1999) according to patients socioeconomic characteristics]</article-title>. <source>Revue d Epidemiologie et de Sante Publique</source>
<volume>50</volume>: <fpage>383</fpage>&#x02013;<lpage>392</lpage>.<pub-id pub-id-type="pmid">12442055</pub-id></mixed-citation></ref><ref id="pmed.1001376-Pagano1"><label>53</label><mixed-citation publication-type="journal">
<name><surname>Pagano</surname><given-names>E</given-names></name>, <name><surname>Filippini</surname><given-names>C</given-names></name>, <name><surname>Di Cuonzo</surname><given-names>D</given-names></name>, <name><surname>Ruffini</surname><given-names>E</given-names></name>, <name><surname>Zanetti</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Factors affecting pattern of care and survival in a population-based cohort of non-small-cell lung cancer incident cases</article-title>. <source>Cancer Epidemiol</source>
<volume>34</volume>: <fpage>483</fpage>&#x02013;<lpage>489</lpage>.<pub-id pub-id-type="pmid">20444663</pub-id></mixed-citation></ref><ref id="pmed.1001376-Patel1"><label>54</label><mixed-citation publication-type="journal">
<name><surname>Patel</surname><given-names>N</given-names></name>, <name><surname>Adatia</surname><given-names>R</given-names></name>, <name><surname>Mellemgaard</surname><given-names>A</given-names></name>, <name><surname>Jack</surname><given-names>R</given-names></name>, <name><surname>Moller</surname><given-names>H</given-names></name> (<year>2007</year>) <article-title>Variation in the use of chemotherapy in lung cancer</article-title>. <source>Br J Cancer</source>
<volume>96</volume>: <fpage>886</fpage>&#x02013;<lpage>890</lpage>.<pub-id pub-id-type="pmid">17342091</pub-id></mixed-citation></ref><ref id="pmed.1001376-Stevens3"><label>55</label><mixed-citation publication-type="journal">
<name><surname>Stevens</surname><given-names>G</given-names></name>, <name><surname>Stevens</surname><given-names>W</given-names></name>, <name><surname>Purchuri</surname><given-names>S</given-names></name>, <name><surname>Kolbe</surname><given-names>J</given-names></name>, <name><surname>Cox</surname><given-names>B</given-names></name> (<year>2009</year>) <article-title>Radiotherapy utilisation in lung cancer in New Zealand: Disparities with optimal rates explained</article-title>. <source>N Z Med J</source>
<volume>122</volume>
<issue>1306</issue>: <fpage>43</fpage>&#x02013;<lpage>54</lpage>.</mixed-citation></ref><ref id="pmed.1001376-Younis1"><label>56</label><mixed-citation publication-type="journal">
<name><surname>Younis</surname><given-names>T</given-names></name>, <name><surname>Al-Fayea</surname><given-names>T</given-names></name>, <name><surname>Virik</surname><given-names>K</given-names></name>, <name><surname>Morzycki</surname><given-names>W</given-names></name>, <name><surname>Saint-Jacques</surname><given-names>N</given-names></name> (<year>2008</year>) <article-title>Adjuvant chemotherapy uptake in non-small cell lung cancer</article-title>. <source>J Thorac Oncol</source>
<volume>3</volume>: <fpage>1272</fpage>&#x02013;<lpage>1278</lpage>.<pub-id pub-id-type="pmid">18978562</pub-id></mixed-citation></ref><ref id="pmed.1001376-Bradley1"><label>57</label><mixed-citation publication-type="journal">
<name><surname>Bradley</surname><given-names>CJ</given-names></name>, <name><surname>Dahman</surname><given-names>B</given-names></name>, <name><surname>Given</surname><given-names>CW</given-names></name> (<year>2008</year>) <article-title>Treatment and Survival Differences in Older Medicare Patients With Lung Cancer as Compared With Those Who Are Dually Eligible for Medicare and Medicaid</article-title>. <source>J Clin Oncol</source>
<volume>26</volume>: <fpage>5067</fpage>&#x02013;<lpage>5073</lpage>.<pub-id pub-id-type="pmid">18794546</pub-id></mixed-citation></ref><ref id="pmed.1001376-Davidoff1"><label>58</label><mixed-citation publication-type="journal">
<name><surname>Davidoff</surname><given-names>AJ</given-names></name>, <name><surname>Tang</surname><given-names>M</given-names></name>, <name><surname>Seal</surname><given-names>B</given-names></name>, <name><surname>Edelman</surname><given-names>MJ</given-names></name> (<year>2010</year>) <article-title>Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non&#x02013;Small-Cell Lung Cancer</article-title>. <source>J Clin Oncol</source>
<volume>28</volume>: <fpage>2191</fpage>&#x02013;<lpage>2197</lpage>.<pub-id pub-id-type="pmid">20351329</pub-id></mixed-citation></ref><ref id="pmed.1001376-Earle1"><label>59</label><mixed-citation publication-type="journal">
<name><surname>Earle</surname><given-names>CC</given-names></name>, <name><surname>Venditti</surname><given-names>LN</given-names></name>, <name><surname>Neumann</surname><given-names>PJ</given-names></name>, <name><surname>Gelber</surname><given-names>RD</given-names></name>, <name><surname>Weinstein</surname><given-names>MC</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Who Gets Chemotherapy for Metastatic Lung Cancer?</article-title>. <source>Chest</source>
<volume>117</volume>: <fpage>1239</fpage>&#x02013;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">10807806</pub-id></mixed-citation></ref><ref id="pmed.1001376-Esnaola1"><label>60</label><mixed-citation publication-type="journal">
<name><surname>Esnaola</surname><given-names>NF</given-names></name>, <name><surname>Gebregziabher</surname><given-names>M</given-names></name>, <name><surname>Knott</surname><given-names>K</given-names></name>, <name><surname>Finney</surname><given-names>C</given-names></name>, <name><surname>Silvestri</surname><given-names>GA</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Underuse of Surgical Resection for Localized, Non-Small Cell Lung Cancer Among Whites and African Americans in South Carolina</article-title>. <source>Ann Thorac Surg</source>
<volume>86</volume>: <fpage>220</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">18573427</pub-id></mixed-citation></ref><ref id="pmed.1001376-Greenwald1"><label>61</label><mixed-citation publication-type="journal">
<name><surname>Greenwald</surname><given-names>HP</given-names></name>, <name><surname>Polissar</surname><given-names>NL</given-names></name>, <name><surname>Borgatta</surname><given-names>EF</given-names></name>, <name><surname>McCorkle</surname><given-names>R</given-names></name>, <name><surname>Goodman</surname><given-names>G</given-names></name> (<year>1998</year>) <article-title>Social Factors, Treatment, and Survival in Early-Stage Non-Small Cell Lung Cancer</article-title>. <source>Am J Public Health</source>
<volume>88</volume>: <fpage>1681</fpage>&#x02013;<lpage>1684</lpage>.<pub-id pub-id-type="pmid">9807536</pub-id></mixed-citation></ref><ref id="pmed.1001376-Hardy1"><label>62</label><mixed-citation publication-type="journal">
<name><surname>Hardy</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>C-C</given-names></name>, <name><surname>Xia</surname><given-names>R</given-names></name>, <name><surname>Cormier</surname><given-names>JN</given-names></name>, <name><surname>Chan</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer</article-title>. <source>Cancer</source>
<volume>115</volume>: <fpage>2199</fpage>&#x02013;<lpage>2211</lpage>.<pub-id pub-id-type="pmid">19365824</pub-id></mixed-citation></ref><ref id="pmed.1001376-Hayman1"><label>63</label><mixed-citation publication-type="journal">
<name><surname>Hayman</surname><given-names>JA</given-names></name>, <name><surname>Abrahamse</surname><given-names>PH</given-names></name>, <name><surname>Lakhani</surname><given-names>I</given-names></name>, <name><surname>Earle</surname><given-names>CC</given-names></name>, <name><surname>Katz</surname><given-names>SJ</given-names></name> (<year>2007</year>) <article-title>Use of Palliative Radiotherapy Among Patients With Metastatic Non-Small-Cell Lung Cancer</article-title>. <source>Int J Radiation Oncology Biol Phys</source>
<volume>69</volume>: <fpage>1001</fpage>&#x02013;<lpage>1007</lpage>.</mixed-citation></ref><ref id="pmed.1001376-Lathan1"><label>64</label><mixed-citation publication-type="journal">
<name><surname>Lathan</surname><given-names>CS</given-names></name>, <name><surname>Neville</surname><given-names>BA</given-names></name>, <name><surname>Earle</surname><given-names>CC</given-names></name> (<year>2008</year>) <article-title>Racial composition of hospitals: Effects on surgery for early-stage non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source>
<volume>26</volume>
<issue>26</issue>: <fpage>4347</fpage>&#x02013;<lpage>4352</lpage>.<pub-id pub-id-type="pmid">18779622</pub-id></mixed-citation></ref><ref id="pmed.1001376-Polednak1"><label>65</label><mixed-citation publication-type="journal">
<name><surname>Polednak</surname><given-names>AP</given-names></name> (<year>2001</year>) <article-title>Disaparities in surgical treatment of early-stage non-small-cell lung cancer</article-title>. <source>Yale J Biol Med</source>
<volume>74</volume>: <fpage>309</fpage>&#x02013;<lpage>314</lpage>.<pub-id pub-id-type="pmid">11769336</pub-id></mixed-citation></ref><ref id="pmed.1001376-Smith1"><label>66</label><mixed-citation publication-type="journal">
<name><surname>Smith</surname><given-names>TJ</given-names></name>, <name><surname>Penberthy</surname><given-names>L</given-names></name>, <name><surname>Desch</surname><given-names>CE</given-names></name>, <name><surname>Whittemore</surname><given-names>M</given-names></name>, <name><surname>Newschaffer</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>Differences in initial treatment patterns and outcomes of lung cancer in the elderly</article-title>. <source>Lung Cancer</source>
<volume>13</volume>: <fpage>235</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">8719064</pub-id></mixed-citation></ref><ref id="pmed.1001376-Bach1"><label>67</label><mixed-citation publication-type="journal">
<name><surname>Bach</surname><given-names>PB</given-names></name>, <name><surname>Cramer</surname><given-names>LD</given-names></name>, <name><surname>Warren</surname><given-names>JL</given-names></name>, <name><surname>Begg</surname><given-names>CB</given-names></name> (<year>1999</year>) <article-title>Racial differences in the treatment of early-stage lung cancer</article-title>. <source>N Engl J Med</source>
<volume>341</volume>: <fpage>1198</fpage>&#x02013;<lpage>1205</lpage>.<pub-id pub-id-type="pmid">10519898</pub-id></mixed-citation></ref><ref id="pmed.1001376-Earle2"><label>68</label><mixed-citation publication-type="journal">
<name><surname>Earle</surname><given-names>CC</given-names></name>, <name><surname>Neumann</surname><given-names>PJ</given-names></name>, <name><surname>Gelber</surname><given-names>RD</given-names></name>, <name><surname>Weinstein</surname><given-names>MC</given-names></name>, <name><surname>Weeks</surname><given-names>JC</given-names></name> (<year>2002</year>) <article-title>Impact of Referral Patterns on the Use of Chemotherapy for Lung Cancer</article-title>. <source>J Clin Oncol</source>
<volume>20</volume>: <fpage>1786</fpage>&#x02013;<lpage>1792</lpage>.<pub-id pub-id-type="pmid">11919235</pub-id></mixed-citation></ref><ref id="pmed.1001376-Lathan2"><label>69</label><mixed-citation publication-type="journal">
<name><surname>Lathan</surname><given-names>CS</given-names></name>, <name><surname>Neville</surname><given-names>BA</given-names></name>, <name><surname>Earle</surname><given-names>CC</given-names></name> (<year>2006</year>) <article-title>The effect of race on invasive staging and surgery in non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source>
<volume>24</volume>: <fpage>413</fpage>&#x02013;<lpage>418</lpage>.<pub-id pub-id-type="pmid">16365180</pub-id></mixed-citation></ref><ref id="pmed.1001376-Ou1"><label>70</label><mixed-citation publication-type="journal">
<name><surname>Ou</surname><given-names>SHI</given-names></name>, <name><surname>Zell</surname><given-names>JA</given-names></name>, <name><surname>Ziogas</surname><given-names>A</given-names></name>, <name><surname>Anton-Culver</surname><given-names>H</given-names></name> (<year>2008</year>) <article-title>Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status</article-title>. <source>Cancer</source>
<volume>112</volume>: <fpage>2011</fpage>&#x02013;<lpage>2020</lpage>.<pub-id pub-id-type="pmid">18361399</pub-id></mixed-citation></ref><ref id="pmed.1001376-Suga1"><label>71</label><mixed-citation publication-type="journal">
<name><surname>Suga</surname><given-names>JM</given-names></name>, <name><surname>Nguyen</surname><given-names>DV</given-names></name>, <name><surname>Mohammed</surname><given-names>SM</given-names></name>, <name><surname>Brown</surname><given-names>M</given-names></name>, <name><surname>Calhoun</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer</article-title>. <source>J Thorac Oncol</source>
<volume>5</volume>: <fpage>1772</fpage>&#x02013;<lpage>1778</lpage>.<pub-id pub-id-type="pmid">20881638</pub-id></mixed-citation></ref><ref id="pmed.1001376-Tammemagi1"><label>72</label><mixed-citation publication-type="journal">
<name><surname>Tammemagi</surname><given-names>CM</given-names></name>, <name><surname>Neslund-Dudas</surname><given-names>C</given-names></name>, <name><surname>Simoff</surname><given-names>M</given-names></name>, <name><surname>Kvale</surname><given-names>P</given-names></name> (<year>2004</year>) <article-title>In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival</article-title>. <source>J Clin Epidemiol</source>
<volume>57</volume>: <fpage>597</fpage>&#x02013;<lpage>609</lpage>.<pub-id pub-id-type="pmid">15246128</pub-id></mixed-citation></ref><ref id="pmed.1001376-Wang1"><label>73</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Kuo</surname><given-names>Y</given-names></name>, <name><surname>Freeman</surname><given-names>J</given-names></name>, <name><surname>Goodwin</surname><given-names>J</given-names></name> (<year>2008</year>) <article-title>Increasing access to medical oncology consultation in older patients with stage II-IIIA non-small-cell lung cancer</article-title>. <source>Med Oncol</source>
<volume>25</volume>: <fpage>125</fpage>&#x02013;<lpage>132</lpage>.<pub-id pub-id-type="pmid">18488153</pub-id></mixed-citation></ref><ref id="pmed.1001376-Yang1"><label>74</label><mixed-citation publication-type="journal">
<name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Cheung</surname><given-names>MC</given-names></name>, <name><surname>Byrne</surname><given-names>MM</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Nguyen</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Do racial or socioeconomic disparities exist in lung cancer treatment?</article-title>
<source>Cancer</source>
<volume>116</volume>: <fpage>2437</fpage>&#x02013;<lpage>2447</lpage>.<pub-id pub-id-type="pmid">20209616</pub-id></mixed-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>NSCLC</term><def><p>non-small cell lung cancer</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item><def-item><term>SCLC</term><def><p>small cell lung cancer</p></def></def-item><def-item><term>SEER</term><def><p>National Cancer Institute's Surveillance, Epidemiology and End Results</p></def></def-item><def-item><term>SEP</term><def><p>socioeconomic position</p></def></def-item><def-item><term>UHCS</term><def><p>universal health care system</p></def></def-item></def-list></glossary></back></article>